Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 1.4.3.4 - monoamine oxidase and Organism(s) Homo sapiens and UniProt Accession P27338

for references in articles please use BRENDA:EC1.4.3.4
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     1 Oxidoreductases
         1.4 Acting on the CH-NH2 group of donors
             1.4.3 With oxygen as acceptor
                1.4.3.4 monoamine oxidase
IUBMB Comments
A mitochondrial outer-membrane flavoprotein (FAD) that catalyses the oxidative deamination of neurotransmitters and biogenic amines . Acts on primary amines, and also on some secondary and tertiary amines. It differs from EC 1.4.3.21, primary-amine oxidase as it can oxidize secondary and tertiary amines but not methylamine. This enzyme is inhibited by acetylenic compounds such as chlorgyline, 1-deprenyl and pargyline but, unlike EC 1.4.3.21 and EC 1.4.3.22 (diamine oxidase), it is not inhibited by semicarbazide.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
UNIPROT: P27338
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Bacteria, Eukaryota, Archaea
Reaction Schemes
Synonyms
monoamine oxidase, mao-b, mao-a, monoamine oxidase a, mao a, mao b, monoamine oxidase b, monoamine oxidase-b, monoamine oxidase-a, semicarbazide-sensitive amine oxidase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
MAO type B
-
monoamine oxidase
-
monoamine oxidase type B
-
monoamine oxidase-A
-
monoaminoxidase B
-
adrenaline oxidase
-
-
-
-
epinephrine oxidase
-
-
-
-
MAO A
MAO B
MAO-A
monoamine oxidase
monoamine oxidase A
monoamine oxidase B
monoamine oxidase-A
monoamine oxidase-B
-
-
monoamine oxidaseA
-
monoamine oxidases A
-
-
monoamine oxidases B
-
-
monoamine-oxidase-A
-
monoamine:O2 oxidoreductase (deaminating)
-
-
-
-
serotonin deaminase
-
-
-
-
tyraminase
-
-
-
-
tyramine oxidase
-
-
-
-
additional information
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Deamination
-
-
-
-
redox reaction
-
-
-
-
oxidation
-
-
-
-
reduction
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
amine:oxygen oxidoreductase (deaminating)
A mitochondrial outer-membrane flavoprotein (FAD) that catalyses the oxidative deamination of neurotransmitters and biogenic amines [3]. Acts on primary amines, and also on some secondary and tertiary amines. It differs from EC 1.4.3.21, primary-amine oxidase as it can oxidize secondary and tertiary amines but not methylamine. This enzyme is inhibited by acetylenic compounds such as chlorgyline, 1-deprenyl and pargyline but, unlike EC 1.4.3.21 and EC 1.4.3.22 (diamine oxidase), it is not inhibited by semicarbazide.
CAS REGISTRY NUMBER
COMMENTARY hide
9001-66-5
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(1R,6S)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane + H2O + O2
?
show the reaction diagram
MAO-B catalyzed ring alpha-carbon oxidation of 3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane is enantioselective with an almost 5fold preference for the (1R,6S) enantiomer based on Vmax/Km values
-
-
?
(1S,6R)-3-methyl-6-phenyl-3-azabicyclo[4.1.0]heptane + H2O + O2
?
show the reaction diagram
MAO-B catalyzed ring alpha-carbon oxidation of 3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane is enantioselective with an almost 5fold preference for the (1R,6S) enantiomer based on Vmax/Km values
-
-
?
1-methyl-4-(1-methyl-1H-pyrrol-2-yl)-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
3-(4-(3-aminopropoxy)butoxy)-N-(thiophen-2-ylmethyl)propan-1-amine + H2O + O2
3-(4-[3-[(thiophen-2-ylmethyl)amino]propoxy]butoxy)propanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
4-phenylbutylamine + H2O + O2
4-phenylbutanal + NH3 + H2O2
show the reaction diagram
proposed pathways for amine oxidation: the amine substrate may bind to oxidised enzyme (E/FADox), leading to the release of product imine via a binary (1) or ternary (2) pathway. The relative contributions of these pathways cannot be determined directly by steady-state approaches. In following pathway 1, the unoccupied reduced enzyme (E/FADred) is generated, to which substrate may also bind. Reoxidation of the E/FADred–S species (pathway 3) bypasses direct regeneration of E/FADox, with the consequence that imine released subsequent to this step, whether through the binary or ternary pathways leading from E/FADred–imine, is a product of substrate binding to a second enzyme species
-
-
?
4-tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
4-tyramine + H2O + O2
2-(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
kynuramine + H2O + O2
4-hydroxyquinoline + NH3 + H2O2
show the reaction diagram
kynuramine + O2
4-hydroxyquinoline + NH3 + H2O2
show the reaction diagram
-
-
-
?
N1-(thiophen-2-ylmethyl)dodecane-1,12-diamine + H2O + O2
12-[(thiophen-2-ylmethyl)amino]dodecanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
N1-benzyl-N1-methyldodecane-1,12-diamine + H2O + O2
12-[benzyl(methyl)amino]dodecanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
N1-benzyldodecane-1,12-diamine + H2O + O2
12-(benzylamino)dodecanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
p-nitrobenzylamine + H2O + O2
4-nitrobenzaldehyde + NH3 + H2O2
show the reaction diagram
p-nitrophenylethylamine + H2O + O2
4-nitrophenylacetaldehyde + NH3 + H2O2
show the reaction diagram
good substrate for wild-type and mutant enzymes Y435H, Y435F, Y435L and Y435W
-
-
?
p-trifluoromethyl-benzylamine + H2O + O2
4-trifluoromethylbenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
phenylethylamine + H2O + O2
phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
r
tyramine + H2O + O2
4-hydroxyphenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
1-methyl-4-(1-methyl-1H-pyrrol-2-yl)-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
-
-
?
1-methyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
i.e. MMTP, is oxidized to the corresponding dihydropyridinium metabolite, MMDP+
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
1-[4-(trifluoromethyl)phenyl]methanamine + H2O + O2
4-(trifluoromethyl)benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + 2 H2O + 3 O2
1-methyl-4-phenyl-2,3-dihydropyridinium + 1-methyl-4-phenylpyridinium + 4 H2O2
show the reaction diagram
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
2-phenylethylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
3-(4-(3-aminopropoxy)butoxy)-N-(thiophen-2-ylmethyl)propan-1-amine + H2O + O2
3-(4-[3-[(thiophen-2-ylmethyl)amino]propoxy]butoxy)propanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
4-tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
substrate for isoform MAO A
-
-
?
4-tyramine + H2O + O2
2-(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
4-tyramine + H2O + O2
4-hydroxyphenylacetaldehyde + NH3 + H2O2
show the reaction diagram
4-tyramine + H2O + O2
?
show the reaction diagram
5-hydroxytryptamine + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
5-methoxy-N,N-dimethyltryptamine + H2O + O2
?
show the reaction diagram
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
dopamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
epinephrine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
kynuramine + H2O + O2
4-hydroxyquinoline + NH3 + H2O2
show the reaction diagram
kynuramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
kynuramine + O2
4-hydroxyquinoline + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
N1-(thiophen-2-ylmethyl)dodecane-1,12-diamine + H2O + O2
12-[(thiophen-2-ylmethyl)amino]dodecanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
N1-benzyl-N1-methyldodecane-1,12-diamine + H2O + O2
12-[benzyl(methyl)amino]dodecanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
N1-benzyldodecane-1,12-diamine + H2O + O2
12-(benzylamino)dodecanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
norepinephrine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
p-tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
phenylbutylamine + H2O + O2
2-phenylbutanal + NH3 + H2O2 + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2 + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
tryptamine + H2O + O2
1H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
tyramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
1-methyl-4-phenylpyridinium is the ultimate product
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
2 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + 2 H2O + 3 O2
1-methyl-4-phenyl-2,3-dihydropyridinium + 1-methyl-4-phenylpyridinium + 4 H2O2
show the reaction diagram
-
activation of the neurotoxin to neurotoxic pyridinium cations. MPTP easily crosses the blood-brain barrier and is preferentially metabolized by MAO-B present in glial cells to 1-methyl-4-phenyl-2,3-dihydropyridinium. This enzymatic metabolite is subsequently oxidized to 1-methyl-4-phenylpyridinium, which is selectively uptaken by dopaminergic cells, producing inhibition of complex I of mitochondria, energy depletion, oxidative stress and cell death
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is metabolically oxidized by alpha-carbon oxidation by MAO enzymes to give 1-methyl-4-phenyl-2,3-dihydropyridinium and hydrogen peroxide, which, in a further step, is readily oxidized to 1-methyl-4-phenylpyridinium, that is a directly-acting neurotoxic substance
-
?
2-phenylethylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
4-tyramine + H2O + O2
4-hydroxyphenylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
in vivo activity, overview
-
-
?
5-hydroxytryptamine + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
5-methoxy-N,N-dimethyltryptamine + H2O + O2
?
show the reaction diagram
-
i.e. 5-MeO-DMT, a psychoactive indolealkylamine drug found in a variety of plant preparations, e.g. Virola snuffs and Ayahuasca, and venom of psychoactive toads, e.g. Colorado River Bufo alvarius. 5-MeO-DMT is known as a nonselective 5-HT receptor agonist. MAO-A eliminates the drug 5-MeO-DMT through oxidative deamination
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
dopamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
epinephrine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
norepinephrine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
tyramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
flavin
8alpha-S-cysteinyl-FAD
1 mol per mol of enzyme
flavin
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-amphetamine
reversible competitive inhibitor
(2-methylprop-2-en-1-yl)hydrazine
-
(2-phenylprop-2-en-1-yl)hydrazine
-
(2E)-1-(4-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one
competitive inhibition
(2E)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
(2E)-2-[(1H-indol-3-yl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 10% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carbothioamide
-
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
-
-
(2E)-2-[1-(2,4-dihydroxy-5-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 8% inhibition
-
(2E)-2-[1-(4-chloro-3-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.3% inhibition
-
(2E)-2-[1-[3-(dihydroxyamino)-4-methoxyphenyl]ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 37.2% inhibition
-
(2E)-3-(2-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
-
(2E)-3-(3-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-(4-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
-
-
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
-
-
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
-
-
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
-
(3E)-7-hydroxy-3-[(4-methoxyphenyl)methylidene]-2,3-dihydro-4H-1-benzopyran-4-one
-
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(5Z)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
L136468, binding mode, overview
(5Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
A6355
(5Z)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
L136662
(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
AS605240, binding mode, overview
(E)-3-(2-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(3,4-dimethoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(3-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-(diethylamino)benzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-(dimethylamino)benzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-chlorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-fluorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(10-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(5-(1,2,3,4-tetrahydroacridin-9-ylamino)pentyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(8-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(9-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methylbenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
(E)-5-(3-chlorostyryl)isatin
-
(E)-5-(3-fluorostyryl)isatin
-
(E)-5-styrylisatin
-
(E)-6-styrylisatin
-
(E)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)-3-(3,4,5-trimethoxybenzylidene)chroman-4-one
-
(E)-7-(6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)-3-(4-methoxybenzylidene)chroman-4-one
-
(E)-7-(8-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)3-(4-methoxybenzylidene)chroman-4-one
-
(E)-8-(3-chlorostyryl)caffeine
(E)-8-styrylcaffeine
reversible MAO-B inhibitor, a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
(R)-deprenyl
i.e. selegiline, a MAO-B inhibitor
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
1,2,3,4-tetrahydroacridin-9-amine
-
1,4-diphenyl-1,3-butadiene
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
1,4-diphenyl-2-butene
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
-
-
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
-
-
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methyl-N-(2-methyl-1H-indol-5-yl)-1lambda4-pyridine-3-carboxamide
-
2,4-dimethoxy-5-hydroxybenzaldehyde
IC50: 0.39 mM
2,6-dimethoxyphenol
IC50: above 0.5 mM, monoamine oxidase B
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(3-hydroxyphenyl)acetamide
6164872
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-phenylacetamide
6163851
2-(2-benzofuranyl)-2-imidazoline
at micromolar concentrations, to a site distinct from the active site on at least two forms of the pure enzyme, probably corresponding to oxidised and reduced enzyme states
2-(4,5-dihydroimidazol-2-yl)-isoquinoline
reversible non-competitive/mixed inhibitor
2-(4,5-dihydroimidazol-2-yl)-quinoline
reversible non-competitive/mixed inhibitor
2-(4-bromophenyl)cyclopropanamine
-
2-(4-methoxyphenyl)cyclopropanamine
-
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
-
-
2-(5,7-dibromobenzofuran-2-yl)-imidazoline
reversible non-competitive/mixed inhibitor
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
-
2-(aminooxy)-1-phenylethanol
-
2-(naphthalen-1-yl)cyclopropanamine
-
2-(thiophen-3-yl)cyclopropanamine
-
2-hydrazinyl-4-(3-nitrophenyl)-1,3-thiazole
0.1 mM, pH 7.4, 10% inhibition
-
2-methoxyphenol
IC50: above 0.5 mM, monoamine oxidase B
2-methyl-5-methylaniline
IC50: above 0.5 mM
2-oxo-2H-chromen-7-yl benzenesulfonate
-
2-phenylcyclopropylamine
moderate isoenzyme selectivity
2-Phenylethylamine
time-dependent, slowly reversible suicide inhibition. Addition of 2-phenylethylamine (10mM) to the enzyme results in immediate bleaching of the absorbance peak at 460 nm, a consequence of rapid reduction of the flavin cofactor by 2-phenylethylamine at steady state
2-[(1E,3E)-4-(3-chlorophenyl)buta-1,3-dien-1-yl]-3,5,7-trimethyl-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
2-[4-(trifluoromethyl)phenyl]cyclopropanamine
-
2-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
3,4-dimethyl-2-oxo-2H-chromen-7-yl 4-methoxybenzenesulfonate
-
3,4-dimethyl-2-oxo-2H-chromen-7-yl benzenesulfonate
-
3,4-dimethyl-7-(2-oxo-2-phenylethoxy)-2H-chromen-2-one
-
3,4-dimethyl-7-[(3-nitrobenzyl)oxy]-2H-chromen-2-one
-
3,4-dimethyl-7-[(pentafluorobenzyl)oxy]-2H-chromen-2-one
-
3,4-dimethyl-7-{[3-(trifluoromethoxy)benzyl]oxy}-2H-chromen-2-one
-
3,5,7-trimethyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
3-(2-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-naphthyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-fluorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
-
-
3-(4-methoxybenzyl)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
3-(4-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(5-oxo-5H-indeno[1,2-c]pyridazin-3-yl)benzonitrile
-
3-(benzyloxy)-6a,10a-dihydro-6H-benzo[c]chromen-6-one
-
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
-
-
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-benzyl-5H-indeno[1,2-c]pyridazin-5-one
-
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
3-methyl-8-(4,4,4-trifluoro-butoxy)indeno[1.2-c]pyridazin-5-one
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
-
3-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
R598127
3-[(E)-2-phenylvinyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-[4-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
4-(2,4-dichlorophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 31% inhibition
-
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
-
-
4-([6-[(4-cyanophenyl)methoxy]-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
-
-
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
IC50: 0.0089 mM, monoamine oxidase B
4-Hydroxy-3-methoxybenzylamine
IC50: 0.382 mM, monoamine oxidase B
4-[[(4-oxo-3,4-dihydroquinazolin-6-yl)oxy]methyl]benzonitrile
-
-
5,7-diethyl-3-methyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
5-(4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl)-1,3-thiazolidine-2,4-dione
i.e. rosiglitazone
5-(4-[(1-methylcyclohexyl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. ciglitazone
5-(4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. troglitazone
5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. pioglitazone, docking of R-pioglitazone in the substrate cavity of MAO-B
6-hydroxy-N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
6-[(3-iodophenyl)methoxy]-3-[(3-iodophenyl)methyl]quinazolin-4(3H)-one
-
-
6-[(3-iodophenyl)methoxy]quinazolin-4(3H)-one
-
-
6-[(4-fluorophenyl)methoxy]-3-[(4-fluorophenyl)methyl]quinazolin-4(3H)-one
-
-
7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(anilinomethyl)-2H-chromen-2-one
-
7-(benzylamino)-3,4-dimethyl-2H-chromen-2-one
-
7-(benzyloxy)-2H-chromen-2-one
-
7-(benzyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(benzyloxy)-4-methyl-2H-chromen-2-one
-
7-(benzyloxy)-4-phenyl-2H-chromen-2-one
-
7-[(3-chlorophenyl)methoxy]-4-(methylaminomethyl)chromen-2-one
-
8-(3-chlorostrylyl)caffeine
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
8-(3-chlorostyryl)caffeine
monoamine oxidase B
amitriptyline
competive inhibition with 2-phenylethylamine as substrate
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
benzylhydrazine
the three-dimensional structures of phenylethylhydrazine- and benzylhydrazine-inhibited MAO B show that alkylation occurs at the N5 position on the re-face of the covalent flavin with loss of the hydrazyl nitrogens, mechanism, the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
Caffeine
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
cinnamyl alcohol
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
cis-2,4,5-trimethoxypropenylbenzene
IC50: 0.362 mM, monoamine oxidase B
cis-N-benzyl-2-methoxycyclopropylamine
high inhibitory action, exhibits a poor isozyme selectivity
-
Clorgyline
clorogyline
-
-
Deprenyl
di(2-hydroxyethyl)methyldodecylammonium
reversible competitive inhibitor
epigallocatechin gallate dimer
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
ethyl 4-hydroxy-3-methoxycinnamate
IC50: 0.0057 mM, monoamine oxidase B
eugenol
IC50: 0.288 mM, monoamine oxidase B
eugenol methyl ether
IC50: 0.269 mM, monoamine oxidase B
indol -2,3-dione
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
iproniazid phosphate
-
-
isatin
KF-17837
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
KW-6002
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
L-deprenyl
inhibition of MAO A and MAO B
ladostigil
-
lamotrigine
its in vivo MAO-B inhibiting effect might contribute in part to its antidepressant activity
lazabemide
metamphetamine
i.e. N-methyl-1-phenyl-2-propanamine
-
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
-
methylene blue
-
moclobemide
mofegiline
mechanism-based irreversible, competitive inhibition versus substrate of MAO-B with a 1:1 molar stoichiometry, also competitively inhibits MAO-A. Effects on UV absorption spectra of flavin, and inhibitor-bound enzyme structure, overview
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-4-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
i.e. ParSL-2, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-B
N-(2-aminoethyl)-4-chlorobenzamide
-
N-(2-methyl-1H-indol-5-yl)benzamide
-
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
-
N-(3',4'-dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3'-chlorophenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3'-fluorophenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-dimethyl-2-oxo-2H-chromen-7-yl)benzamide
-
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442
N-(3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}phenyl)acetamide
-
N-benzyl-12-isothiocyanato-N-methyldodecan-1-amine
irreversible inhibition with respect to isoform MAO-A, competitive inhibition with respect to isoform MAO-B
N-methyl-N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-phenyl-1H-indazole-5-carboxamide
-
N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-propargyl-l(R)-aminoindan
i.e. rasagiline. N-Propargyl-l(R)-aminoindan is well tolerated and effective in the treatment of early Parkinson's disease and as adjunctive treatment in levodopa-treated patients with Parkinson's disease experiencing motor fluctuations
N1,N12-dibenzyldodecane-1,12-diamine
-
N1-(3-aminopropyl)-N4-(3-((naphthalen-2-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((pyridin-3-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((thiophen-2-ylmethyl)amino)propyl)butane-1,4-diamine
mixed-type reversible inhibition with respect to isoform MAO-A and MAO-B
N1-benzyl-spermine
-
norharman
inhibition of MAO B
o-eugenol
IC50: above 0.5 mM, monoamine oxidase B
p-nitrobenzylamine
substrate for wild-type enzyme, competitive inhibitor for mutant enzyme Y435L
Pargyline
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
Phenelzine
concentration-dependent inhibition
phentermine
i.e. 2-methyl-1-phenyl-2-propanamine
Phenylethylhydrazine
the three-dimensional structures of phenylethylhydrazine- and benzylhydrazine-inhibited MAO B show that alkylation occurs at the N5 position on the re-face of the covalent flavin with loss of the hydrazyl nitrogens, mechanism, the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
phenylhydrazine
weak binding
pioglitazone
-
raisin extract
-
-
rasagiline
rhodiocyanoside A
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
rhodioloside B
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
rosiridin
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
safinamide
salidroside
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
selegiline
sembragiline
-
-
trans,trans-farnesol
monoamine oxidase B
trans-2,4,5-trimethoxypropenylbenzene
IC50: 0.338 mM, monoamine oxidase B
trans-2-phenylcyclopropylamine
2-PCPA
tranylcypromine
triandrin
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
tyrosol
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
-
[(5E)-2,4-dioxo-5-(phenylimino)-1,3-thiazolidin-3-yl]acetonitrile
R598119
[(E)-1,3-dipropyl-7-methyl-8-(2-(3-thienyl)ethenyl)]xanthine
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
-
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
the complex 1 is a potent MAO-B inhibitor
-
(+/-)-6-hydroxytrypargine
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata, synthesized by reaction of 5-hydroxytryptamine hydrochloride with N-(3-[1,3]dioxolan-2-yl-propyl)-guanidine sulfate, overview
(1E,2E)-3-(furan-2-yl)-N-(prop-2-yn-1-yl)prop-2-en-1-imine
-
-
(1R,2R)-(-)-psi-ephedrine
(1S,2S)-(+)-psi-ephedrine
(1Z)-2-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.39
(2-methylprop-2-en-1-yl)hydrazine
-
(2-phenylprop-2-en-1-yl)hydrazine
-
(2E)-1,3-diphenylprop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methylphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-phenylprop-2-en-1-one
-
-
(2E)-1-[4-(benzyloxy)phenyl]-3-(4-chlorophenyl)prop-2-en-1-one
-
-
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-(3-hydroxyphenyl)ethanamide
-
-
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-phenylethanamide
-
-
(2E)-2-[(1H-indol-3-yl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 43% inhibition
-
(2E)-2-[(2-chloro-3-methoxyphenyl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 17% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carbothioamide
0.1 mM, pH 7.4, 32% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
-
-
(2E)-2-[1-(2,4,5-trifluorophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 23% inhibition
-
(2E)-2-[1-(2,4-dihydroxy-5-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 30% inhibition
-
(2E)-2-[1-(4-chloro-3-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 13% inhibition
-
(2E)-2-[1-(4-iodophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 25% inhibition
-
(2E)-2-[1-[3-(dihydroxyamino)-4-methoxyphenyl]ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 19% inhibition
-
(2E)-3-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one
-
inhibits MAO-A and MAO-B
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
-
-
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
-
-
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-fluorophenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E,6E)-farnesol
-
-
(2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide
-
i.e. safinamide, a potent selective and reversible MAO-B inhibitor, occurs in two polymorphic forms. Both forms are orthorhombic and regarded as conformational polymorphs due to the differences in the orientation of the 3-fluorobenzyloxy and propanamide groups. Both structures pack with layers in the ac plane, structure overview
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(5E)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-(3-bromobenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-(4-chlorobenzylidene)-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(4-hydroxy-2,5-dimethoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(4-hydroxy-3-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-benzylidene-2-imino-1,3-thiazolidin-4-one
-
-
(5E)-5-benzylidene-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-[(3,5-dibromo-4-hydroxycyclohexa-1,4-dien-1-yl)methylidene]-1,3-thiazolidine-2,4-dione
-
-
(5R)-3-(3-fluoro-4-morpholin-4-ylphenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R,5'R)-3,3'-[1,4-diazepane-1,4-diylbis(3-fluorobenzene-4,1-diyl)]bis[5-(hydroxymethyl)-1,3-oxazolidin-2-one]
IC50: 0.001mM, at 0.15 mM kynuramine
(5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one
-
(5S)-5-(aminomethyl)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-1,3-oxazolidin-2-one
-
(5S)-5-(aminomethyl)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-1,3-oxazolidin-2-one
-
(aminomethyl)trimethylsilane
-
-
(E)-1-(2,3-dimethoxy-6-methylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloro-4-fluorophenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloroquinolin-3-yl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-methoxy-2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-phenoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(5-bromo-2-methoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-phenyl-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-5-(3-chlorostyryl)isatin
-
(E)-5-(3-fluorostyryl)isatin
-
(E)-5-styrylisatin
-
(E)-6-styrylisatin
-
(E)-N-(prop-2-yn-1-yl)-1-(3,4,5-trimethoxyphenyl)methanimine
-
-
(E)-N-(prop-2-yn-1-yl)-1-[4-(pyridin-2-yl)phenyl]methanimine
-
-
(N-cyclopropyl-alpha-methylbenzylamine)
the inhibitor forms an adduct that allows reoxidation of the flavin on denaturation
(R)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
(R)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(R)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(R)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
(R)-amphetamine
(R)-deprenyl
-
(R,S)-amphetamine
(S)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
(S)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(S)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(S)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3-dimethyl-5-nitro-1H-indazole
-
-
1,4-diphenyl-1,3-butadiene
-
-
1,4-diphenyl-2-butene
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-((1H-indol-3-yl)-methylene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(coumarin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(furan-2-yl)ethylidene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(naphthalen-2-yl)ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclopentylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclopentylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(4-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(benzodioxol-5-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(naphthalen-1-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(octan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-3-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cycloheptylidene-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclohexylidenehydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclopentylidenehydrazine
-
-
1-(4-chlorobutyl)-5-nitro-1H-indazol-3-ol
-
-
1-(4-guanidinobutoxy)-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-(N-methylthiocarbamoyl)-3-(3-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(3-methylphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-chlorophenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-fluorophenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
1-benzyl-5-nitro-1H-indazol-3-ol
-
-
1-guanidino-6-hydroxy-3,5-dihydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
-
-
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
-
-
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methyl-4-phenylpyridinium
-
1-methyl-5-nitro-1H-indazol-3-ol
-
inhibits MAO-B by 34% at 0.015 mM
1-O-n-octyl-beta-D-glucopyranoside
-
at concentrations well below the critical micelle concentration
1-phenylcyclopropylamine
the inhibitor forms an irreversible flavin adduct
1-thiocarbamoyl-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
2,2'-dipyridyl disulfide
-
-
2,4-dichloro-N'-(nonan-5-yl)benzohydrazide
-
-
2,4-dichlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.92
2,4-dichlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.03
2,4-dimethoxy-5-hydroxybenzaldehyde
IC50: 0.042 mM, monoamine oxidase A
2,6-dimethoxyphenol
IC50: 0.0624 mM, monoamine oxidase A
2-(2,4-dichlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(2-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-ethoxylpyridin-3-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3,4,5-trimethoxyphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3,5-dimethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3-methylphenyl)-4-(butoxycarbonylethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
-
-
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
-
-
2-(4'-butoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-butoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-ethoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-ethoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-methoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-methoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-propoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-propoxyphenyl)thiomorpholine oxalate
-
-
2-(4-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-ethylphenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-ethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-fluorophenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
-
-
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
-
2-(aminooxy)-1-phenylethanol
-
2-(benzo[d][1,3]dioxol-5-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(methyl[4-[(E)-(prop-2-yn-1-ylimino)methyl]phenyl]amino)ethanol
-
-
2-(naphthalen-2-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-chloro-5-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
2-ethoxy-6-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-ethoxy-N'-(nonan-5-yl)nicotinohydrazide
-
-
2-hydrazinyl-4-(3-nitrophenyl)-1,3-thiazole
0.1 mM, pH 7.4, 6% inhibition
-
2-methoxyphenol
IC50: 0.175 mM, monoamine oxidase A
2-methyl-5-methylaniline
IC50: 0.15 mM, monoamine oxidase A
2-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.45
2-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.18
2-oxo-N-(2,3,5,6-tetrafluoropyridin-4-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(pentafluorophenyl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(propan-2-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-[3-(trifluoromethyl)phenyl]-2H-chromene-3-carboxamide
-
-
2-oxo-N-[4-(propan-2-yl)phenyl]-2H-chromene-3-carboxamide
-
-
2-phenyl-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-phenylcyclopropylamine
2-phenylthiomorpholin-5-one
-
-
2-phenylthiomorpholine oxalate
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
2-[(E)-(prop-2-yn-1-ylimino)methyl]benzene-1,4-diol
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
3,4,5-trimethoxy-N'-(nonan-5-yl)benzohydrazide
-
-
3,4-dimethoxy-(benzylidene)-prop-2-ynylamine
-
-
3,4-dimethoxyaniline
IC50: 0.131 mM, monoamine oxidase A
3,4-dimethoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.88
3,4-dimethoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.52
3,5-dimethyl-(1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine
-
-
3,5-dimethyl-N'-(nonan-5-yl)benzohydrazide
-
-
3-(4-hydroxyphenyl)-2-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)propanoic acid
-
-
3-(4-hydroxyphenyl)propionic acid
-
-
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
-
-
3-(benzyloxy)-5-nitro-1H-indazole
-
-
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
-
-
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-benzyl-5-nitro-1H-indazole
-
-
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-hydroxyphenylacetic acid
-
-
3-methoxy-1-methyl-5-nitro-1H-indazole
-
inhibits MAO-B by 52% at 0.015 mM
3-methoxy-5-nitro-1H-indazole
-
-
3-methoxyphenol
IC50: 0.024 mM, monoamine oxidase A
3-methyl-5-nitro-1H-indazole
-
-
3-[(5E)-5-benzylidene-2,4-dioxo-1,3-thiazolidin-3-yl]propanenitrile
-
-
3-[(5E)-5-benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(E)-(prop-2-yn-1-ylimino)methyl]naphthalen-2-ol
-
-
4-(2,4-dichlorophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 25% inhibition
-
4-(2,4-dichlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-dichlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2-bromophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 24% inhibition
-
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
-
-
4-(4-chlorophenyl)-2-(2-cycloheptylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclohexylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-fluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-methoxyphenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-methoxyphenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
4-chlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.42
4-chlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.0
4-ethyl-N'-(nonan-5-yl)benzohydrazide
-
-
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
IC50: 0.0134 mM, monoamine oxidase A
4-Hydroxy-3-methoxybenzylamine
IC50: 0.13 mM, monoamine oxidase A
4-hydroxy-3-methoxyphenethyl alcohol
IC50: 0.18 mM, monoamine oxidase A
4-hydroxy-3-methoxyphenyl acetone
IC50: 0.0302 mM, monoamine oxidase A
4-hydroxyphenylacetic acid
-
-
4-methoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.72
4-methoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.3
4-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 6.69
4-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.67
4-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.0
4-oxo-4H-chromene-3-carboxylic acid
-
specific for MAO-B
4-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]phenyl methanesulfinate
-
-
4-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
-
-
4-[2-(2-cycloheptylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoic acid
-
-
5-(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-hydroxy-3,5-dimethylbenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(aminomethyl)-3-aryl-2-oxazolidinones
-
-
5-chloro-2-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
5-chloro-2-[(prop-2-yn-1-ylamino)methyl]phenol
-
-
5-nitro-1-(pyridin-2-ylmethyl)-1H-indazol-3-ol
-
-
5-nitroindazole
-
inhibits MAO-B by 98.5% at 0.015 mM
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-1,3-thiazolidine-2,4-dione ammoniate (1:1)
-
-
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-2-imino-1,3-thiazolidin-4-one
-
-
6-nitroindazole
-
inhibits MAO-B by 89% at 0.015 mM, also inhibits MAO-A
7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin
-
7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin
-
7-nitroindazole
-
inhibits MAO-B by 35% at 0.015 mM
8-(3-chloro)styrylcaffeine
-
-
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
amphetamine
Azure Blue
-
-
befloxatone
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site
benzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 8.14
benzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 5.92
benzhydrylidene-prop-2-ynyl-amine
-
-
benzylhydrazine
the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
beta-carbolines
-
competitive reversible and potent inhibitor
brofaromine
ciglitazone
-
-
cis-2,4,5-trimethoxypropenylbenzene
IC50: 0.142 mM, monoamine oxidase A
cis-N-benzyl-2-methoxycyclopropylamine
high inhibitory action, exhibits a poor isozyme selectivity
-
clorgiline
-
-
Clorgyline
cyanidin
-
competitive interaction of cyanidin with MAO A plus a mixed competitive and non-competitive mode of interaction of cyanidin with MAO B
cyanidin-3,5-diglucoside
-
-
cyanidin-3-O-beta-D-galactoside
-
-
cyanidin-3-O-beta-D-glucoside
-
mixed competitive and non-competitive mode of interaction with both enzyme isozymes
cyanidin-3-O-beta-D-rutinoside
-
-
cyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.69
cyclopentanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 6.85
D-amphetamine
delphinidin
-
-
delphinidin-3-O-beta-D-glucoside
-
-
Deprenyl
di(2-hydroxyethyl)methyldodecylammonium ion
-
a biocide, inhibits MAO-B
esuprone
-
inhibits MAO-A reversibly
ethyl 4-hydroxy-3-methoxycinnamate
IC50: 0.0247 mM, monoamine oxidase A
ethyl 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoate
-
-
ethyl-4-hydroxy-3-methoxyphenylacetate
IC50: 0.081 mM, monoamine oxidase A
eugenol
IC50: 0.0344 mM, monoamine oxidase A
eugenol methyl ether
IC50: 0.11 mM, monoamine oxidase A
farnesol
-
-
Harmaline
harmalol
-
identification by HPLC-ESI-mass spectrometry
harman
Harmane
harmine
harmol
-
identification by HPLC-ESI-mass spectrometry
Iproniazid
-
-
Iproniazide
isatin
isocarboxazide
isoproniazid
-
inhibits MAO-A and MAO-B irreversibly
lazabemide
LU-53439
-
inhibits MAO-B reversibly
malvidin
-
-
malvidin 3-O,5-O-di-beta-D-glucoside
-
-
malvidin-3-O-beta-D-galactoside
-
-
malvidin-3-O-beta-D-glucoside
-
-
metamphetamine
i.e. N-methyl-1-phenyl-2-propanamine
-
metanephrine
IC50: 0.252 mM, monoamine oxidase A
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
-
methyl 4'-[(E)-(prop-2-yn-1-ylimino)methyl]biphenyl-4-carboxylate
-
-
methylene blue
moclobemide
mofegiline
-
a vinyl fluoroamine
N'-(2-cyanoethyl)-4-ethylbenzohydrazide
-
-
N'-(nonan-5-yl)-2-naphthohydrazide
-
-
N'-(nonan-5-yl)benzo[d][1,3]dioxole-5-carbohydrazide
-
-
N'-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carbohydrazide
-
-
N,N'-bis[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]butanediamide
IC50: 0.09 mM, at 0.15 mM kynuramine
N,N'-[(1,5-dioxopentane-1,5-diyl)bis[piperazine-4,1-diyl(3-fluorobenzene-4,1-diyl)[(5R)-2-oxo-1,3-oxazolidine-3,5-diyl]methanediyl]]diacetamide
IC50: 0.0005 mM, at 0.15 mM kynuramine
N-((4-isopropylphenyl)-2-oxo-2H-chromene-3-carboxamide)-amide
-
-
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-3-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
i.e. ParSL-3, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-A
N-(2,3-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-difluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-aryl-carboxamide
-
N-(2-aminoethyl)-p-chlorobenzamide
N-(2-benzylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-chloro-6-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-methyl-6-chlorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-methyl-6-chlorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-8-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-8-methyl-2-oxo-7-(2-phenylethyl)-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442
N-(3-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-trifluoromethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-ethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-isopropylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-isopropylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methanesulfonylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(biphenyl-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(butan-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(cycloheptylidenemethyl)-4-(3-methoxyphenyl)-1,3-thiazol-2-amine
-
-
N-(prop-2-ynyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-([(5S)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
N-([(5S)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
N-benzyl-12-isothiocyanato-N-methyldodecan-1-amine
irreversible inhibition with respect to isoform MAO-A, competitive inhibition with respect to isoform MAO-B
N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methylprop-2-yn-1-amine
-
i.e. pargyline
N-benzylprop-2-yn-1-amine
-
-
N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-cyclohexyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-isobutyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-isopropyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-phenyl-1H-indazole-5-carboxamide
-
N-[3-(2,4-dichlorophenoxy)propyl]-N-methyl-prop-2-yn-1-amine
-
i.e. clorgiline
N-[4-(methylsulfonyl)phenyl]-2-oxo-2H-chromene-3-carboxamide
-
-
N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
-
N1,N12-dibenzyldodecane-1,12-diamine
-
N1-(3-aminopropyl)-N4-(3-((naphthalen-2-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((pyridin-3-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((thiophen-2-ylmethyl)amino)propyl)butane-1,4-diamine
mixed-type reversible inhibition with respect to isoform MAO-A and MAO-B
N1-benzyl-spermine
-
norharman
o-eugenol
IC50: 0.101 mM, monoamine oxidase A
oleamide
-
inhibits MAO B
p-(propylthio)-phenylisopropylamine
-
Pargyline
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
pelargonidin
-
-
pelargonidin 3-O,5-O-di-beta-D-glucoside
-
-
peonidin
-
-
peonidin-3-O-beta-D-glucoside
-
-
petunidin
-
-
Phenelzine
-
-
phentermine
Phenylethylhydrazine
the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
phenylhydrazine
weak binding
pirlindole
an MAO A specific reversible inhibitor
R-(-)-deprenyl
R-deprenyl
-
-
R-rasagiline
-
-
raisin extract
-
-
rasagiline
Ro 19-6327
-
-
Ro 41-1049
-
-
rosiglitazone
-
-
safinamide
selegiline
syringic acid
-
-
tetrahydroharmine
-
identification by HPLC-ESI-mass spectrometry
tetrindole
toloxatone
trans-2,4,5-trimethoxypropenylbenzene
IC50: 0.124 mM, monoamine oxidase A
trans-2-phenylcyclopropylamine
trans-trans-1,4-diphenyl-1,3-butadiene
-
-
tranylcypromine
troglitazone
-
-
vanillic acid
-
-
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
-
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
SRY protein
SRY and Sp1 form a transcriptional complex and synergistically activate MAO A transcription, overview
-
transcription factor Sp1
SRY and Sp1 form a transcriptional complex and synergistically activate MAO A transcription, overview
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.221
(1R,6S)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane
pH 7.0, 37°C
0.753
(1S,6R)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane
pH 7.0, 37°C
0.016 - 0.68
2-Phenylethylamine
0.401
3-(4-(3-aminopropoxy)butoxy)-N-(thiophen-2-ylmethyl)propan-1-amine
isoform MAO B, at pH 7.4 and 37°C
0.0109 - 8.8
benzylamine
0.03
kynuramine
-
0.018
N1-(thiophen-2-ylmethyl)dodecane-1,12-diamine
isoform MAO B, at pH 7.4 and 37°C
0.012
N1-benzyl-N1-methyldodecane-1,12-diamine
isoform MAO B, at pH 7.4 and 37°C
0.05
N1-benzyldodecane-1,12-diamine
isoform MAO B, at pH 7.4 and 37°C
0.09 - 0.76
p-nitrobenzylamine
0.005 - 0.22
p-nitrophenylethylamine
0.05 - 2
p-trifluoromethyl-benzylamine
0.192
serotonin
monoamine oxidase B
0.033 - 0.04
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1.2
3-(4-(3-aminopropoxy)butoxy)-N-(thiophen-2-ylmethyl)propan-1-amine
isoform MAO A, at pH 7.4 and 37°C
0.19
5-hydroxytryptamine
-
-
0.077 - 2.133
benzylamine
0.111 - 1.36
dopamine
0.0161 - 5.123
kynuramine
0.08
N1-(thiophen-2-ylmethyl)dodecane-1,12-diamine
isoform MAO A, at pH 7.4 and 37°C
0.044
N1-benzyl-N1-methyldodecane-1,12-diamine
isoform MAO A, at pH 7.4 and 37°C
0.043
N1-benzyldodecane-1,12-diamine
isoform MAO A, at pH 7.4 and 37°C
0.33
O2
-
-
0.19
p-tyramine
-
-
0.89
phenethylamine
11°C
0.0089 - 0.055
phenylbutylamine
0.0022 - 1.48
Phenylethylamine
0.0863 - 2.92
serotonin
0.066
tryptamine
-
-
0.079
tyramine
-
-
additional information
additional information
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.012 - 3.82
2-Phenylethylamine
0.028 - 6.08
benzylamine
0.185 - 0.38
p-nitrobenzylamine
1.8 - 2.24
p-nitrophenylethylamine
0.455 - 2.85
p-trifluoromethyl-benzylamine
0.16 - 0.29
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
0.079 - 10
benzylamine
0.249
dopamine
11°C
1.07 - 2.5
kynuramine
1.481
phenethylamine
11°C
1.83 - 2.34
phenylbutylamine
0.897 - 3.1
Phenylethylamine
0.426 - 18.6
serotonin
5.3
tyramine
-
-
additional information
additional information
-
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1.78 - 33.3
benzylamine
3.7 - 59.2
kynuramine
43.3 - 253.3
phenylbutylamine
2.7 - 300
Phenylethylamine
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.506 - 2.56
(+)-amphetamine
0.00036
(2E)-1-(4-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one
at pH 7.4 and 37°C
0.00022
(2E)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
at pH 7.4 and 37°C
0.00028
(2E)-3-(2-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
at pH 7.4 and 37°C
0.002 - 0.00423
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
0.00035
(2E)-3-(3-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
at pH 7.4 and 37°C
0.00027
(2E)-3-(4-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
at pH 7.4 and 37°C
0.00801 - 0.175
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
0.00106
(3E)-7-hydroxy-3-[(4-methoxyphenyl)methylidene]-2,3-dihydro-4H-1-benzopyran-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.026622
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.011244
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000293
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.001356
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.006267
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000062
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000716
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000222
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.030444
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000066
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.00008
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000138
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000951
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000613
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000453
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000062
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.033956
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000284
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.0018622
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.025244
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.021822
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000058
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.00179
(E)-3-(2-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.01973
(E)-3-(3,4-dimethoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.0022
(E)-3-(3-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.00103
(E)-3-(4-(dimethylamino)benzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.0154
(E)-3-(4-chlorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.00109
(E)-3-(4-fluorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.00343
(E)-3-(4-methoxybenzylidene)-7-(10-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.00116
(E)-3-(4-methoxybenzylidene)-7-(5-(1,2,3,4-tetrahydroacridin-9-ylamino)pentyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.000401
(E)-3-(4-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.000518
(E)-3-(4-methoxybenzylidene)-7-(8-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.000437
(E)-3-(4-methoxybenzylidene)-7-(9-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.00124
(E)-3-(4-methylbenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.00019 - 0.001
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.0014 - 0.0125
(E)-5-(3-chlorostyryl)isatin
0.00056 - 0.0022
(E)-5-(3-fluorostyryl)isatin
0.00031 - 0.0011
(E)-5-styrylisatin
0.0006 - 0.0045
(E)-6-styrylisatin
0.00136
(E)-7-(6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)-3-(4-methoxybenzylidene)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.00156
(E)-7-(8-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)3-(4-methoxybenzylidene)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.00003 - 0.000081
(E)-8-(3-chlorostyryl)caffeine
MAO-B
0.000094 - 0.00286
(E)-8-styrylcaffeine
MAO-B
0.00052 - 0.0033
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.0007
1,4-diphenyl-2-butene
monoamine oxidase B
0.0055 - 0.0399
1-methyl-N-(2-methyl-1H-indol-5-yl)-1lambda4-pyridine-3-carboxamide
0.00789 - 0.326
2-(2-benzofuranyl)-2-imidazoline
0.0652 - 0.513
2-(4,5-dihydroimidazol-2-yl)-isoquinoline
0.0817 - 0.385
2-(4,5-dihydroimidazol-2-yl)-quinoline
0.0329
2-(4-bromophenyl)cyclopropanamine
inhibition of MAO-B
0.0866
2-(4-methoxyphenyl)cyclopropanamine
inhibition of MAO-B
0.008 - 0.114
2-(5,7-dibromobenzofuran-2-yl)-imidazoline
0.0098
2-(naphthalen-1-yl)cyclopropanamine
inhibition of MAO-B
1.548
2-(thiophen-3-yl)cyclopropanamine
inhibition of MAO-B
0.000104
2-[(1E,3E)-4-(3-chlorophenyl)buta-1,3-dien-1-yl]-3,5,7-trimethyl-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
MAO-B
0.0077
2-[4-(trifluoromethyl)phenyl]cyclopropanamine
inhibition of MAO-B
0.00003 - 0.0026
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
0.000149 - 0.000153
3,5,7-trimethyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
MAO-B
0.00111
3-(4-methoxybenzyl)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
isoform MAO-B, at pH 8.0 and 37°C
0.00033 - 0.0082
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
0.00043 - 0.002
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.0683 - 0.0757
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
0.00000274
5,7-diethyl-3-methyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
MAO-B
0.0001
7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin
25°C, pH 7.5
0.0004
7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin
25°C, pH 7.5
0.0002
8-(3-chlorostyryl)caffeine
monoamine oxidase B
0.0177 - 0.55
amitriptyline
0.00305 - 0.00383
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.026 - 0.048
benzylhydrazine
0.022
Caffeine
MAO-B
0.027267
clorogyline
pH and temperature not specified in the publication
-
0.0000087
Deprenyl
pH and temperature not specified in the publication
0.00298 - 0.0799
di(2-hydroxyethyl)methyldodecylammonium
0.211
eugenol
monoamine oxidase B
0.002 - 0.012
isatin
0.0000022 - 0.0000045
KW-6002
MAO-B
0.297
metamphetamine
pH and temperature not specified in the publication
-
0.0013
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
inhibition of MAO-B
0.00145
moclobemide
at pH 7.4 and 37°C
0.000028 - 0.0011
mofegiline
0.022
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
pH 7.5
0.015
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-4-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
inhibition of MAO-B
0.00165 - 0.0395
N-(2-methyl-1H-indol-5-yl)benzamide
0.003 - 0.0183
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
0.000055
N-(3',4'-dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide
pH 7.5, 25°C
-
0.000017
N-(3'-chlorophenyl)-4-oxo-4H-chromene-3-carboxamide
pH 7.5, 25°C
-
0.000031
N-(3'-fluorophenyl)-4-oxo-4H-chromene-3-carboxamide
pH 7.5, 25°C
-
0.138
phentermine
pH and temperature not specified in the publication
0.015 - 0.128
Phenylethylhydrazine
0.791
phenylhydrazine
pH 7.5, MAO-B, determined from Kitz-Wilson plots of the hydrazine concentration dependence on rates in enzyme inhibition at 15°C
0.00045
safinamide
25°C, pH 7.5
0.000055 - 0.00035
selegiline
0.0023
trans,trans-farnesol
monoamine oxidase B
0.0136
trans-2-phenylcyclopropylamine
inhibition of MAO-B
0.0038
tranylcypromine
pH and temperature not specified in the publication
0.001063
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.001606
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.00007142
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000034
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.0005343
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.00036
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.005886
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000131
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.011429
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000054
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.00006285
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.0007371
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.00014
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000126
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.00038
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.011429
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000306
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.008543
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.012657
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.0114
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.000154
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.004429
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
pH and temperature not specified in the publication
-
0.0012
(5R)-3-(3-fluoro-4-morpholin-4-ylphenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one
pH 7.2, 30°C
0.00016
(5R)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
pH 7.2, 30°C
0.00034
(5R)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
pH 7.2, 30°C
0.116
(5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one
pH 7.2, 30°C
0.0057
(5S)-5-(aminomethyl)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-1,3-oxazolidin-2-one
pH 7.2, 30°C
0.023
(5S)-5-(aminomethyl)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-1,3-oxazolidin-2-one
pH 7.2, 30°C
0.0056
(E)-5-(3-chlorostyryl)isatin
inhibition of MAO-A
0.022
(E)-5-(3-fluorostyryl)isatin
inhibition of MAO-A
0.00078
(E)-5-styrylisatin
inhibition of MAO-A
0.0022
(E)-6-styrylisatin
inhibition of MAO-A
1.4 - 2.7
(N-cyclopropyl-alpha-methylbenzylamine)
0.000051 - 0.0013
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
0.00014 - 0.00018
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
0.001 - 0.007
1,4-diphenyl-1,3-butadiene
0.0081 - 0.0345
1,4-diphenyl-2-butene
0.0035 - 0.0045
1-methyl-4-phenylpyridinium
7.3 - 12.8
1-phenylcyclopropylamine
0.000048 - 0.1
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
0.000038 - 0.1
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
0.00046 - 0.01
2-(4'-butoxyphenyl)thiomorpholin-5-one
0.000068 - 0.0025
2-(4'-butoxyphenyl)thiomorpholine oxalate
0.0169 - 0.06
2-(4'-ethoxyphenyl)thiomorpholin-5-one
0.0021 - 0.0096
2-(4'-ethoxyphenyl)thiomorpholine oxalate
0.1
2-(4'-methoxyphenyl)thiomorpholin-5-one
0.0162 - 0.1
2-(4'-methoxyphenyl)thiomorpholine oxalate
0.0024 - 0.04
2-(4'-propoxyphenyl)thiomorpholin-5-one
0.00013 - 0.0066
2-(4'-propoxyphenyl)thiomorpholine oxalate
0.2 - 0.31
2-phenylcyclopropylamine
0.1
2-phenylthiomorpholin-5-one
0.1
2-phenylthiomorpholine oxalate
0.000102
5-nitroindazole
-
pH 7.4, 37°C, MAO-B
0.00067
6-nitroindazole
-
pH 7.4, 37°C, MAO-B
0.0157
7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin
25°C, pH 7.5
0.011
7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin
25°C, pH 7.5
0.0074
7-nitroindazole
-
pH 7.4, 37°C, MAO-B
0.00027 - 0.0017
8-(3-chloro)styrylcaffeine
0.00043 - 0.00059
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000023 - 0.00033
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000036 - 0.00023
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.00018 - 0.00037
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.00034 - 0.0011
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.02
amphetamine
-
-
0.0000026
Azure Blue
pH and temperature not specified in the publication
-
1.95 - 2.096
benzylhydrazine
0.00000128 - 0.000012
Clorgyline
0.0204 - 0.0586
cyanidin
0.0474 - 0.0611
cyanidin-3-O-beta-D-glucoside
0.0115 - 0.28
D-amphetamine
0.0019214
Deprenyl
pH and temperature not specified in the publication
0.026
eugenol
monoamine oxidase A
0.0023 - 0.018
farnesol
0.00005554 - 0.00013
harman
0.14 - 0.55
Harmane
0.000005
harmine
pH and temperature not specified in the publication
0.0015 - 0.36
isatin
0.017
metamphetamine
pH and temperature not specified in the publication
-
0.0235
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
inhibition of MAO-A
0.000027 - 0.00101
methylene blue
0.011 - 0.2
moclobemide
pH and temperature not specified in the publication
0.212
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
pH 7.5
0.268
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-3-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
inhibition of MAO-A
0.0016
N-([(5S)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
pH 7.2, 30°C
0.005
N-([(5S)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
pH 7.2, 30°C
0.02
N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
pH 7.2, 30°C
0.00112 - 0.0012
norharman
0.000011 - 0.00003
p-(propylthio)-phenylisopropylamine
0.127 - 6.682
phentermine
0.047 - 0.05
Phenylethylhydrazine
0.205 - 0.523
phenylhydrazine
0.0033 - 0.01
rasagiline
0.000021 - 0.365
safinamide
0.000009
tetrindole
pH and temperature not specified in the publication
0.0373
trans-2-phenylcyclopropylamine
inhibition of MAO-A
0.007
trans-trans-1,4-diphenyl-1,3-butadiene
-
-
0.0077 - 0.017
tranylcypromine
additional information
additional information
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.02
(2-methylprop-2-en-1-yl)hydrazine
Homo sapiens
-
0.071
(2-phenylprop-2-en-1-yl)hydrazine
Homo sapiens
-
9.95
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carbothioamide
Homo sapiens
pH 7.4, temperature not specified in the publication
-
17.7
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
Homo sapiens
pH 7.4, temperature not specified in the publication
-
0.0077 - 0.00983
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
0.00547
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.00142
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.000193
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.01882 - 0.663
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
0.0599
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0253
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00066
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00305
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0141
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00014
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00161
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0005
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0685
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00015
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00018
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00031
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00214
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00138
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00102
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00014
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0764
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00064
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0419
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0568
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0491
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00013
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.027
(5Z)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.000082
(5Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.000195
(5Z)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.013
(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.00044 - 0.0039
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.0000207
(E)-5-(3-chlorostyryl)isatin
Homo sapiens
-
0.000444
(E)-5-(3-fluorostyryl)isatin
Homo sapiens
-
0.0000417
(E)-5-styrylisatin
Homo sapiens
-
0.0000301
(E)-6-styrylisatin
Homo sapiens
-
0.0012 - 0.0125
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.0022
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
Homo sapiens
-
0.00307
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0139
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0125
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
Homo sapiens
pH 7.4, 37°C
-
0.027
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00732
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0135
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00087
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.00129
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.0157
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.00231
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.0208 - 0.0926
1-methyl-N-(2-methyl-1H-indol-5-yl)-1lambda4-pyridine-3-carboxamide
0.39
2,4-dimethoxy-5-hydroxybenzaldehyde
Homo sapiens
IC50: 0.39 mM
0.5
2,6-dimethoxyphenol
Homo sapiens
IC50: above 0.5 mM, monoamine oxidase B
0.011
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(3-hydroxyphenyl)acetamide
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.022
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-phenylacetamide
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.00797
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
8.2
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
Homo sapiens
-
0.45
2-(aminooxy)-1-phenylethanol
Homo sapiens
-
0.5
2-methoxyphenol
Homo sapiens
IC50: above 0.5 mM, monoamine oxidase B
0.5
2-methyl-5-methylaniline
Homo sapiens
IC50: above 0.5 mM
0.00006 - 0.0098
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
0.000532
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00982
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00119
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0356
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0251
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0471
3-acetyl-1-hydroxy-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.018
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0676
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0135
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
Homo sapiens
pH 7.4, 37°C
-
0.00399
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00119
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000734
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00105
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000605
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000178
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0191
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00279
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00076 - 0.031
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
0.00099 - 0.0077
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.1759 - 0.259
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
0.056
3-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.0035
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
Homo sapiens
pH 7.4, temperature not specified in the publication
-
0.000847
4-([6-[(4-cyanophenyl)methoxy]-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
Homo sapiens
pH and temperature not specified in the publication
-
0.0089
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
Homo sapiens
IC50: 0.0089 mM, monoamine oxidase B
0.382
4-Hydroxy-3-methoxybenzylamine
Homo sapiens
IC50: 0.382 mM, monoamine oxidase B
0.0158
4-[[(4-oxo-3,4-dihydroquinazolin-6-yl)oxy]methyl]benzonitrile
Homo sapiens
pH and temperature not specified in the publication
-
0.000225
5-(4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.000298
5-(4-[(1-methylcyclohexyl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.000832
5-(4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.000048
5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.0414
6-[(3-iodophenyl)methoxy]-3-[(3-iodophenyl)methyl]quinazolin-4(3H)-one
Homo sapiens
pH and temperature not specified in the publication
-
0.00635
6-[(3-iodophenyl)methoxy]quinazolin-4(3H)-one
Homo sapiens
pH and temperature not specified in the publication
-
0.000685
6-[(4-fluorophenyl)methoxy]-3-[(4-fluorophenyl)methyl]quinazolin-4(3H)-one
Homo sapiens
pH and temperature not specified in the publication
-
0.00207
7-[(3-chlorophenyl)methoxy]-4-(methylaminomethyl)chromen-2-one
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.00889 - 0.0116
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.362
cis-2,4,5-trimethoxypropenylbenzene
Homo sapiens
IC50: 0.362 mM, monoamine oxidase B
20.27
Clorgyline
Homo sapiens
pH and temperature not specified in the publication
0.06135
clorogyline
Homo sapiens
pH and temperature not specified in the publication
-
0.000019 - 0.0000196
Deprenyl
0.0057
ethyl 4-hydroxy-3-methoxycinnamate
Homo sapiens
IC50: 0.0057 mM, monoamine oxidase B
0.288
eugenol
Homo sapiens
IC50: 0.288 mM, monoamine oxidase B
0.269
eugenol methyl ether
Homo sapiens
IC50: 0.269 mM, monoamine oxidase B
0.008566 - 368.4
isatin
0.0371
ladostigil
Homo sapiens
isoform MAO-B, at pH 8.0 and 37°C
0.000091
lazabemide
0.0016
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
Homo sapiens
inhibition of MAO-B
0.00384 - 0.15
N-(2-methyl-1H-indol-5-yl)benzamide
0.00696 - 0.0694
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
0.00000108
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000000386
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000000586
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000144
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000152
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000159
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.0000384
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000662
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000000679
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00808
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000117
N-phenyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.5
o-eugenol
Homo sapiens
IC50: above 0.5 mM, monoamine oxidase B
0.000188
Pargyline
Homo sapiens
isoform MAO-B, at pH 8.0 and 37°C
0.0005
pioglitazone
Homo sapiens
pH and temperature not specified in the publication
0.000048 - 0.039
safinamide
0.033
selegiline
Homo sapiens
pH and temperature not specified in the publication
0.000006
sembragiline
Homo sapiens
pH and temperature not specified in the publication
-
0.338
trans-2,4,5-trimethoxypropenylbenzene
Homo sapiens
IC50: 0.338 mM, monoamine oxidase B
0.00065
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
Homo sapiens
-
0.00229
[(5E)-2,4-dioxo-5-(phenylimino)-1,3-thiazolidin-3-yl]acetonitrile
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.09
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.0245
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.081
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.015 - 0.039
(+)-6-hydroxytrypargine
0.008 - 0.034
(-)-6-hydroxytrypargine
0.01665 - 0.1374
(1E,2E)-3-(furan-2-yl)-N-(prop-2-yn-1-yl)prop-2-en-1-imine
14.86 - 88
(1R,2R)-(-)-psi-ephedrine
1.77 - 234
(1S,2S)-(+)-psi-ephedrine
0.35
(2-methylprop-2-en-1-yl)hydrazine
Homo sapiens
-
0.0013
(2-phenylprop-2-en-1-yl)hydrazine
Homo sapiens
-
0.00141
(2E)-1,3-diphenylprop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00103
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methylphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.01876
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-phenylprop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.011
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-(3-hydroxyphenyl)ethanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.02 - 2
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-phenylethanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0056
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
Homo sapiens
pH 7.4, temperature not specified in the publication
-
0.0000051 - 0.00495
(2E)-3-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one
0.0000044
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00125
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00016
(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.000071
(2E)-3-(4-chlorophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.000031
(2E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.000054
(2E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00222
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.00459
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.00405
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.05
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-fluorophenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00045
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00372
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00562
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00025
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00012
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00187
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00126
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0206
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00046
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0522
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00019
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00022
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00258
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00049
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00044
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00133
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
40
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00107
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0299
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0443
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0399
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00054
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0155
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.027
(5E)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000082
(5E)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000195
(5E)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.00607
(5E)-5-(3-bromobenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.03648
(5E)-5-(4-chlorobenzylidene)-3-methyl-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.03165
(5E)-5-(4-hydroxy-2,5-dimethoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00249
(5E)-5-(4-hydroxy-3-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.013
(5E)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.02405
(5E)-5-benzylidene-2-imino-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.01051
(5E)-5-benzylidene-3-methyl-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00102
(5E)-5-[(3,5-dibromo-4-hydroxycyclohexa-1,4-dien-1-yl)methylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.001
(5R,5'R)-3,3'-[1,4-diazepane-1,4-diylbis(3-fluorobenzene-4,1-diyl)]bis[5-(hydroxymethyl)-1,3-oxazolidin-2-one]
Homo sapiens
IC50: 0.001mM, at 0.15 mM kynuramine
0.00348 - 0.00527
(E)-1-(2,3-dimethoxy-6-methylphenyl)-N-(prop-2-yn-1-yl)methanimine
0.00019 - 0.00065
(E)-1-(2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
0.00137 - 0.00161
(E)-1-(2-chloro-4-fluorophenyl)-N-(prop-2-yn-1-yl)methanimine
0.00298 - 0.00828
(E)-1-(2-chloroquinolin-3-yl)-N-(prop-2-yn-1-yl)methanimine
0.00019 - 0.00063
(E)-1-(4-methoxy-2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
0.0001 - 0.00048
(E)-1-(4-phenoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
0.00171 - 0.00219
(E)-1-(5-bromo-2-methoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
0.00018 - 0.00717
(E)-1-phenyl-N-(prop-2-yn-1-yl)methanimine
0.0000207
(E)-5-(3-chlorostyryl)isatin
Homo sapiens
-
0.000444
(E)-5-(3-fluorostyryl)isatin
Homo sapiens
-
0.0000417
(E)-5-styrylisatin
Homo sapiens
-
0.0000301
(E)-6-styrylisatin
Homo sapiens
-
0.00055 - 0.00439
(E)-N-(prop-2-yn-1-yl)-1-(3,4,5-trimethoxyphenyl)methanimine
0.00016 - 0.00114
(E)-N-(prop-2-yn-1-yl)-1-[4-(pyridin-2-yl)phenyl]methanimine
0.0991 - 4.03
(R)-amphetamine
0.0244 - 3
(R,S)-amphetamine
0.098
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
Homo sapiens
-
0.000152 - 0.00372
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
0.0004 - 0.000546
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
0.000414 - 0.0008
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-((1H-indol-3-yl)-methylene)-hydrazine
0.00556 - 0.00697
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(coumarin-3-yl)-ethylidene)hydrazine
0.000333 - 0.00168
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(furan-2-yl)ethylidene)-hydrazine
0.000455 - 0.00381
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)-ethylidene)hydrazine
0.000116 - 0.0037
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)-ethylidene)hydrazine
0.00055 - 0.000636
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)-ethylidene)hydrazine
0.0000122 - 0.000737
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazine
0.0000266 - 0.000836
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclopentylidene)hydrazine
0.0000727 - 0.000679
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine
0.000231 - 0.00145
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclopentylidene)hydrazine
0.0000355 - 0.000749
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(4-methylcyclohexylidene)hydrazine
0.000875
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(benzodioxol-5-ylmethylene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.000343
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)-hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00678
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.00115 - 0.00672
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine
0.0036
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(naphthalen-1-ylmethylene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00138
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(octan-2-ylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.000872 - 0.00131
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-2-ylidene)hydrazine
0.000772 - 0.000824
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-3-ylidene)hydrazine
0.00443 - 0.00507
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
0.000538 - 0.00291
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine
0.000698 - 0.00114
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine
0.000458 - 0.00049
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine
0.0000295 - 0.00178
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cycloheptylidene-hydrazine
0.0000318 - 0.00191
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclohexylidenehydrazine
0.000592 - 0.00106
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclopentylidenehydrazine
0.0713
1-(N-methylthiocarbamoyl)-3-(3-methoxyphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0534
1-(N-methylthiocarbamoyl)-3-(3-methylphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0348
1-(N-methylthiocarbamoyl)-3-(4-chlorophenyl)-4-methyl-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.051
1-(N-methylthiocarbamoyl)-3-(4-fluorophenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0137
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0494
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0168
1-(N-methylthiocarbamoyl)-3-(4-methylphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.000447
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0179
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0216
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
Homo sapiens
pH 7.4, 37°C
-
0.117
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0022
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0166
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.000049
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.000184
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.000175
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.000529
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.0155
1-thiocarbamoyl-3-(4-methoxyphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0846
1-thiocarbamoyl-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0181
1-thiocarbamoyl-3-(4-methylphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.042
2,4-dimethoxy-5-hydroxybenzaldehyde
Homo sapiens
IC50: 0.042 mM, monoamine oxidase A
0.0624
2,6-dimethoxyphenol
Homo sapiens
IC50: 0.0624 mM, monoamine oxidase A
0.00094 - 0.05928
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
0.000016 - 0.007229
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
0.000004 - 0.01028
2-(2-cycloheptylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
0.003925 - 0.005025
2-(2-cycloheptylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
0.00092 - 0.009612
2-(2-cycloheptylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
0.000011 - 0.01785
2-(2-cycloheptylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
0.000027 - 0.01485
2-(2-cycloheptylidenehydrazinyl)-4-phenyl-1,3-thiazole
0.000652 - 0.04575
2-(2-cyclohexylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
0.000004 - 0.0001752
2-(2-cyclohexylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
0.007509 - 0.01196
2-(2-cyclohexylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
0.003689 - 0.02373
2-(2-cyclohexylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
0.000086 - 0.02415
2-(2-cyclohexylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
0.000116 - 0.04835
2-(2-cyclohexylidenehydrazinyl)-4-phenyl-1,3-thiazole
0.000284 - 0.05451
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
0.000003 - 0.002318
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
0.00004 - 0.004436
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
0.000164 - 0.001055
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
0.000134 - 0.002019
2-(2-cyclopentylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
0.000094 - 0.000344
2-(2-cyclopentylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
0.000296 - 0.007883
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
0.0222
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.036
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
Homo sapiens
-
0.25
2-(aminooxy)-1-phenylethanol
Homo sapiens
-
0.00388 - 0.00991
2-(methyl[4-[(E)-(prop-2-yn-1-ylimino)methyl]phenyl]amino)ethanol
0.00104 - 0.01062
2-chloro-5-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
0.00088 - 0.00137
2-ethoxy-6-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
0.175
2-methoxyphenol
Homo sapiens
IC50: 0.175 mM, monoamine oxidase A
0.15
2-methyl-5-methylaniline
Homo sapiens
IC50: 0.15 mM, monoamine oxidase A
0.000143
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000032
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000711 - 0.04124
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
0.00014 - 0.00243
2-[(E)-(prop-2-yn-1-ylimino)methyl]benzene-1,4-diol
0.005477 - 0.008109
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
0.000362 - 0.02088
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
0.000259 - 0.03422
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
0.000014 - 0.000051
3,4-dimethoxy-(benzylidene)-prop-2-ynylamine
0.131
3,4-dimethoxyaniline
Homo sapiens
IC50: 0.131 mM, monoamine oxidase A
0.000048 - 0.00283
3,5-dimethyl-(1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine
0.2729
3-(4-hydroxyphenyl)-2-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)propanoic acid
Homo sapiens
-
pH and temperature not specified in the publication
11.52
3-(4-hydroxyphenyl)propionic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.000813
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00357
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00317
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0419
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0157
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0214
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.115
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0456
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
Homo sapiens
pH 7.4, 37°C
-
0.0138
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000092
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000458
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00132
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00004
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000023
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0222
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00963
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
17.75
3-hydroxyphenylacetic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.024
3-methoxyphenol
Homo sapiens
IC50: 0.024 mM, monoamine oxidase A
0.00229
3-[(5E)-5-benzylidene-2,4-dioxo-1,3-thiazolidin-3-yl]propanenitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.6043
3-[(5E)-5-benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.00026 - 0.00084
3-[(E)-(prop-2-yn-1-ylimino)methyl]naphthalen-2-ol
0.02681 - 0.0447
4-(2,4-dichlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.009446 - 0.08149
4-(2,4-dichlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000014 - 0.03796
4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000091 - 0.0195
4-(2,4-difluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000578
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
Homo sapiens
pH 7.4, temperature not specified in the publication
-
0.000477 - 0.006182
4-(4-chlorophenyl)-2-(2-cycloheptylidenehydrazinyl)-1,3-thiazole
0.000211 - 0.002911
4-(4-chlorophenyl)-2-(2-cyclohexylidenehydrazinyl)-1,3-thiazole
0.000262 - 0.00716
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
0.01313 - 0.03522
4-(4-chlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.002411 - 0.01522
4-(4-chlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000204 - 0.04356
4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000043 - 0.04546
4-(4-fluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.002373 - 0.002762
4-(4-methoxyphenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.005763 - 0.0312
4-(4-methoxyphenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.0134
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
Homo sapiens
IC50: 0.0134 mM, monoamine oxidase A
0.13
4-Hydroxy-3-methoxybenzylamine
Homo sapiens
IC50: 0.13 mM, monoamine oxidase A
0.18
4-hydroxy-3-methoxyphenethyl alcohol
Homo sapiens
IC50: 0.18 mM, monoamine oxidase A
0.0302
4-hydroxy-3-methoxyphenyl acetone
Homo sapiens
IC50: 0.0302 mM, monoamine oxidase A
20.28
4-hydroxyphenylacetic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.047
4-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]phenyl methanesulfinate
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.056
4-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000046 - 0.004327
4-[2-(2-cycloheptylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
0.000053 - 0.004837
4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
0.000221 - 0.000644
4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
0.000026 - 0.03103
4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
0.000061 - 0.006994
4-[2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
0.00238
5-(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.01606
5-(4-hydroxy-3,5-dimethylbenzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.00225
5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.0009 - 0.0365
5-chloro-2-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
0.00089 - 0.00234
5-chloro-2-[(prop-2-yn-1-ylamino)methyl]phenol
0.00099
5-nitroindazole
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.0008
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-1,3-thiazolidine-2,4-dione ammoniate (1:1)
Homo sapiens
-
pH and temperature not specified in the publication
0.3089
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-2-imino-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00252
6-nitroindazole
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.0278
7-nitroindazole
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00124 - 0.00177
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000068 - 0.00094
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000107 - 0.00067
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000542 - 0.00107
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.00101 - 0.00315
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000032 - 0.00011
benzhydrylidene-prop-2-ynyl-amine
0.142
cis-2,4,5-trimethoxypropenylbenzene
Homo sapiens
IC50: 0.142 mM, monoamine oxidase A
0.038
clorgiline
Homo sapiens
pH and temperature not specified in the publication
-
0.0000012 - 0.0634
Clorgyline
0.0295
cyanidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.113 - 0.152
cyanidin-3,5-diglucoside
0.0359 - 0.0464
cyanidin-3-O-beta-D-galactoside
0.0343
cyanidin-3-O-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0332 - 0.0351
cyanidin-3-O-beta-D-rutinoside
0.0348 - 0.038
delphinidin
0.0294 - 0.0314
delphinidin-3-O-beta-D-glucoside
0.0023 - 3.3
Deprenyl
0.0247
ethyl 4-hydroxy-3-methoxycinnamate
Homo sapiens
IC50: 0.0247 mM, monoamine oxidase A
0.081
ethyl-4-hydroxy-3-methoxyphenylacetate
Homo sapiens
IC50: 0.081 mM, monoamine oxidase A
0.0344
eugenol
Homo sapiens
IC50: 0.0344 mM, monoamine oxidase A
0.11
eugenol methyl ether
Homo sapiens
IC50: 0.11 mM, monoamine oxidase A
0.00656 - 0.00754
Iproniazide
0.0187 - 0.0221
malvidin
0.0616 - 0.0733
malvidin 3-O,5-O-di-beta-D-glucoside
0.0341 - 0.0393
malvidin-3-O-beta-D-galactoside
0.0368 - 0.0478
malvidin-3-O-beta-D-glucoside
0.252
metanephrine
Homo sapiens
IC50: 0.252 mM, monoamine oxidase A
0.0271
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
Homo sapiens
inhibition of MAO-A
0.00234 - 0.00536
methyl 4'-[(E)-(prop-2-yn-1-ylimino)methyl]biphenyl-4-carboxylate
0.361 - 0.3614
moclobemide
0.09
N,N'-bis[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]butanediamide
Homo sapiens
IC50: 0.09 mM, at 0.15 mM kynuramine
0.0005
N,N'-[(1,5-dioxopentane-1,5-diyl)bis[piperazine-4,1-diyl(3-fluorobenzene-4,1-diyl)[(5R)-2-oxo-1,3-oxazolidine-3,5-diyl]methanediyl]]diacetamide
Homo sapiens
IC50: 0.0005 mM, at 0.15 mM kynuramine
0.00287
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.00042
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.00764
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
10
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
10
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.000202
N-(cycloheptylidenemethyl)-4-(3-methoxyphenyl)-1,3-thiazol-2-amine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000038
N-benzyl-N-methylprop-2-yn-1-amine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00401 - 0.1088
N-benzylprop-2-yn-1-amine
0.01
N-phenyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.0000022
N-[3-(2,4-dichlorophenoxy)propyl]-N-methyl-prop-2-yn-1-amine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.101
o-eugenol
Homo sapiens
IC50: 0.101 mM, monoamine oxidase A
0.0268 - 0.0426
pelargonidin
0.1173 - 0.242
pelargonidin 3-O,5-O-di-beta-D-glucoside
0.0221 - 0.0305
peonidin
0.0381 - 0.0407
peonidin-3-O-beta-D-glucoside
0.0315 - 0.0432
petunidin
0.000017 - 0.0687
R-(-)-deprenyl
45 - 223.5
safinamide
54.35
selegiline
Homo sapiens
pH and temperature not specified in the publication
4.16
syringic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.00392
toloxatone
0.124
trans-2,4,5-trimethoxypropenylbenzene
Homo sapiens
IC50: 0.124 mM, monoamine oxidase A
3.89
vanillic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0028
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
Homo sapiens
-
0.002
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.001
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.006
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
additional information
additional information
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.0125
-
-
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.5
assay at
7.5
assay at
7.75
-
soluble enzyme
additional information
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5.5 - 11.8
-
no activity below and above
6.5 - 9.5
-
7.5 - 10
-
about 50% of activity maximum at pH 7.5 and 10
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
20
assay at
30
-
assay at
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
MAO-B elevation in mouse brain astrocytes results in Parkinsons pathology
Manually annotated by BRENDA team
activity selectively increases in MAO-B activity in human gliomas when compared with meningiomas or non-tumoural tissue
Manually annotated by BRENDA team
MAO B is the only isoform in platelets and lymphocytes
Manually annotated by BRENDA team
activity selectively increases in MAO-B activity in human gliomas when compared with meningiomas or non-tumoural tissue
Manually annotated by BRENDA team
in human subcutaneous adipose tissue, the adipocyte-enriched fraction exhibits seven-fold higher amine oxidase activity and contains 3- to 7-fold higher levels of mRNAs encoded by MAO-A and MAO-B genes than the stroma-vascular fraction. MAO-A gene accounts for the majority of the respective MAO and SSAO activities in human adipose tissue. Most of the SSAO and MAO found in adipose tissue originated from mature adipocytes
Manually annotated by BRENDA team
in human subcutaneous adipose tissue, the adipocyte-enriched fraction exhibits seven-fold higher amine oxidase activity and contains 3- to 7-fold higher levels of mRNAs encoded by MAO-A and MAO-B genes than the stroma-vascular fraction. MAO-A gene accounts for the majority of the respective MAO and SSAO activities in human adipose tissue. Most of the SSAO and MAO found in adipose tissue originated from mature adipocytes
Manually annotated by BRENDA team
-
of adrenal gland
Manually annotated by BRENDA team
MAO-A prevents basal epithelial cells from differentiating into secretory cells. Inhibition of MAO-A is a key factor in promoting this process. Increased expression of MAO-A in highgrade prostate cancer may be an important contributor to its de-differentiated phenotype
Manually annotated by BRENDA team
-
predominantly B form
Manually annotated by BRENDA team
-
of lymphatic vessel
Manually annotated by BRENDA team
-
predominantly B form
Manually annotated by BRENDA team
-
-
Manually annotated by BRENDA team
-
endothelial cells
Manually annotated by BRENDA team
-
predominantly B form
Manually annotated by BRENDA team
-
acinar cells, entroacinar cells, follicular cells and parafolicular cells
Manually annotated by BRENDA team
MAOA activity and gene expression is upregulated in different brain areas of Alzheimer's disease patients, including the pineal gland. Increased pineal MAOA activity might contribute to the reduced pineal melatonin production in Alzheimer's disease. Alzheimer's disease patients carrying long MAOA-VNTR genotype (consisting of 3.5- or 4-repeat alleles) show higher MAOA gene expression and activity than the short-genotyped Alzheimer's disease patients (i.e., 3-repeat allele). MAOA-VNTR affects the activity and gene expression of MAOA in the brain of Alzheimer's disease patients, and is involved in the changes of monoamine metabolism
Manually annotated by BRENDA team
-
is highly expressed in basal cells of the normal prostatic epithelium and in poorly differentiated, aggressive prostate cancer
Manually annotated by BRENDA team
male cell line
Manually annotated by BRENDA team
from females. The MAO-A gene is expressed from only one of the two alleles in each female cell
Manually annotated by BRENDA team
-
of duodenum, lung, blood vessels, spleen
Manually annotated by BRENDA team
additional information
-
no activity in connective tissue of heart and pancreas, endothelial cells of blood vessels, Brunner gland cells, interstitial cells of kidney, gamma cells of of Langerhans islets, alpha-cells of Langerhans islets
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
outer, membrane may have a role in controlling substrate binding, C-terminal transmembrane helix protrudes from each monomer and anchors the protein to the membrane, several apolar loops exposed on the protein surface are located in proximity of the C-terminal helix, providing additional membrane-binding interactions
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug target
malfunction
the first step of the bioactivation of the Parkinsonian-inducing pro-neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP, is catalyzed by MAO-B, resulting in the ultimate product, 1-methyl-4-phenylpyridinium, a mitochondrial toxin that causes selective degeneration of nigrostriatal dopaminergic neurons in humans and experimental animals
metabolism
drug target
malfunction
metabolism
physiological function
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
AOFB_HUMAN
520
1
58763
Swiss-Prot
other Location (Reliability: 2)
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
59163
-
x * 59163, electrospray mass spectroscopy, including one covalent FAD, MAO-B
59474
-
x * 60000, SDS-PAGE, x * 59474, electrospray mass spectroscopy, including one covalent FAD, MAO-B
60000
-
x * 60000, SDS-PAGE, x * 59474, electrospray mass spectroscopy, including one covalent FAD, MAO-B
60512
64000
-
x * 64000, SDS-PAGE
65000
-
x * 65000, SDS-PAGE
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
dimer
dimer
-
MAO-B is 100% dimeric, whereas MAO A exist only fractionally to 50% in its dimeric form
monomer
monomer or dimer
MAOA is partly dimeric in the mitochondrial outer membrane and in octyl beta-D-glucopyranoside micelles
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
flavoprotein
acetylated protein
flavoprotein
phosphoprotein
MAO A is phosphorylated at Ser209, which does not play a role in enzyme regulation, overview
additional information
-
lipid binding can cause significant alterations in properties of the enzyme
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
crystal structures of human MAO B in complex with the three inhibitors (safinamide, 7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin or 7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin) reveal that they all bind noncovalently to the enzyme
sitting-drop vapor diffusion method, crystal structures of MAO B in complex with trans,trans-farnesol and that of the I199F MAO B mutant protein
sitting-drop vapor diffusion method, mutant enzymes Y435H, Y435F, Y435L, Y435W and wild-type enzyme in complex with p-nitrobenzylamine
sitting-drop vapour diffusion method. Crystal structures of MAO B in complex with four of the N-propargylaminoindane class of MAO B inhibitors, rasagiline, N-propargyl-1(S)-aminoindane, 6-hydroxy-N-propargyl-1(R)-aminoindane, and N-methyl-N-propargyl-1(R)-aminoindane are determined at a resolution of better than 2.1 A. Rasagiline, 6-hydroxy-N-propargyl-1(R)-aminoindane, and N-methyl-N-propargyl-1(R)-aminoindane adopt essentially the same conformation with the extended propargyl chain covalently bound to the flavin and the indane ring located in the rear of the substrate cavity. N-propargyl-1(S)-aminoindane binds with the indane ring in a flipped conformation with respect to the other inhibitors, which causes a slight movement of the Tyr326 side chain
vapour diffusion method at 4°C with a precipitant solution consisting of 12% w/v PEG 4000, 100 mM N-(2-acetamido)-2-iminodiacetic acid, pH 6.5, 70 mM lithium sulfate. Determination of structure at 3 A resolution
MAO-A, X-ray diffraction structure determination at 2.2 A resolution. MAO-B in complex with a range of inhibitors, X-ray diffraction structure determination at 1.65 A resolution. The human MAO-A monomer species is more likely to crystallize than its dimeric form
-
sitting-drop vapour diffusion method,1.7 A structure of the reversible isatin-MAO-B complex, 2.3 A structure of the 1,4-diphenyl-2-butene-MAO-B complex, 2.2 A structure of the tranylcypromine-MAO B complex, 2.4 A structure of the N-(2-aminoethyl)-p-chlorobenzamide-MAO-B complex, 3.1 A structure of the lauryldimethylamine N-oxide-MAO-B complex
-
three-dimensional structure of the enzyme in complex with different reversible (isatin, 1,4-diphenyl-2-butene) and irreversible inhibitors (pargyline, N-(2,aminoethyl)-p-chlorobenzamide, and trans-2-phenylcyclopropylamine), up to 1.7 A resolution
-
using 12% (w/v) polyethylene glycol 4000, 100 mM N-(2-acetamido)-2-iminodiacetic acid buffer pH 6.5, and 70 mM lithium sulfate
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
E142K
a MAOB mutant
I199A
mutant of MAO-B, shows reduced inhibition by (E)-5-styrylisatin and (E)-6-styrylisatin compared to wild-type MAO-B
Y435F
kcat/KM for benzylamine is 21.3fold lower than wild-type value, kcat/KM for p-trifluoromethyl-benzylamine is 40fold lower than wild-type value, kcat/KM for p-nitrobenzylamine is 4.1fold lower than wild-type value, kcat/KM for phenylethylamine is 35.9fold lower than wild-type value, kcat/KM for p-nitrophenylethylamine is 8.3fold lower than wild-type value
Y435H
kcat/KM for benzylamine is 120fold lower than wild-type value, kcat/KM for p-trifluoromethyl-benzylamine is 13fold lower than wild-type value, kcat/KM for p-nitrobenzylamine is 4.4fold lower than wild-type value, kcat/KM for phenylethylamine is 1037fold lower than wild-type value, kcat/KM for p-nitrophenylethylamine is 45.2 fold lower than wild-type value
Y435L
kcat/KM for benzylamine is 128fold lower than wild-type value, kcat/KM for p-trifluoromethyl-benzylamine is 58fold lower than wild-type value, kcat/KM for phenylethylamine is 15.2fold lower than wild-type value, kcat/KM for p-nitrophenylethylamine is 2.7fold lower than wild-type value
Y435W
kcat/KM for benzylamine is 9524fold lower than wild-type value, kcat/KM for phenylethylamine is 13889fold lower than wild-type value, kcat/KM for p-nitrophenylethylamine is 23fold lower than wild-type value
C374A
mutation of surface cysteine 374 to alanine alters substrate turnover and inactivation by cyclopropylamines
C397A
-
expressed protein catalytically inactive
C397H
-
expressed protein catalytically inactive
D123A
-
2.4fold increase in Km-value for phenylethylamine, 3.3fold increase in IC50-value for clorgyline, 3.3fold increase in IC50-value for deprenyl
D132A
-
2.2fold increase in Km-value for serotonin,1.8fold increase in IC50-value for clorgyline, 3.9fold increase in IC50-value for deprenyl
I199A
-
the mutant exhibits catalytic properties with 4fold increased amine Km but unaltered kcat values
I199A/Y326A
-
the mutant exhibits catalytic properties with 75fold increased amine Km but unaltered kcat values. The mutant shows inhibitor binding properties more similar to those of isoform MAO A than to isoform MAO B. Benzylamine is a poor substrate for the double mutant
I199F
-
the bulky Phe side chain impedes such conformational flexibility, reduces the space of the entrance cavity and interferes with the binding of MAO B-specific inhibitors
K151E
a MAOA mutant
K296A
-
no activity with phenylethylamine
K305A
-
no detectable activity with serotonin
S209A
site-directed mutagenesis of the phosphorylation site. The MAO A S209A mutant exhibits similar catalytic properties to those of wild-type enzyme, its catalytic activity is reduced by 1.5-3.7fold compared to the wild-type MAO A
S209E
site-directed mutagenesis of the phosphorylation site. Compared with purified wild-type and S209A MAO A proteins, the S209G MAO A mutant shows 10fold reduced kcat values and 10fold increased Km values compared to the wild-type enzymesignificant differences in covalent flavin fluorescence yield, circular dichroism spectra and thermal stability
W388A
-
no activity with phenylethylamine
W397A
-
no detectable activity with serotonin
Y398F
-
3.5fold increase in Km-value for phenylethylamine, 7.9fold increase in IC50-value for clorgyline, 15.5fold increase in IC50-value for deprenyl
Y398S
-
no activity with phenylethylamine
Y407F
Y407S
-
no detectable activity with serotonin
Y435F
-
9.6fold increase in Km-value for phenylethylamine, 8.6fold increase in IC50-value for clorgyline, 130fold increase in IC50-value for deprenyl
Y435S
-
no activity with phenylethylamine
Y444F
Y444S
-
no detectable activity with serotonin
additional information
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0
stable for at least 120 min without losing activity
15
below, enzyme expressed in Saccharomyces cerevisiae, 60 min stable
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
membranes containing human MAO-A can be immobilized in an immobilized artificial stationary phase with retention of enzymatic activity
-
membranes containing human MAO-B can be immobilized in an immobilized artificial stationary phase with retention of enzymatic activity
-
ORGANIC SOLVENT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Triton X-100
-
solubilization of MAO-A and MAO-B alters the energies of activation and Km for a number of substrates
additional information
-
1-O-n-octyl-beta-D-glucopyranoside, solubilizes enzyme without dramatically altering the lipid microenviroment, a state analogous to the native species
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-20°C, in 50% glycerol v/v for up to 5 months without measurable loss of activity
4°C, enzyme desalted by G-25 gel filtration, stable for 30 days
considerable stability to handling and storage, MAO-B
-
frozen ammonium sulfate precipitate dissolved in 0.1 M phosphate buffer, pH 7.4, 50% loss of activity after 2 months
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant wild-type and mutant MAOB from Pichia pastoris KM71 cell mitochondria partially as mitochondrial outer membrane-bound proteins
purification of large quantities of recombinant enzyme from Pichia pastoris or Saccharomyces cerevisiae. Native MAO-A from placenta
-
recombinant MAO A from Pichia pastoris strain KM17H by anion exchange chromatography, ultrafiltration, and dialysis in presence of 20% glycerol and inhibitor D-amphetamine
recombinant wild-type and mutant MAOA from Pichia pastoris KM71 cell mitochondria partially as mitochondrial outer membrane-bound proteins
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in Pichia pastoris
expression in Pichia pastoris
expression of MAO-A and MAO-B in baculovirus infected BTI insect cells
expression of MAO-B in Pichia pastoris mitochondria, recombinant MAO-B is situated on the cytosolic face of the outer membrane in Pichia mitochondria
expression of mutant enzymes in Pichia pastoris
expression of wild-type and mutant MAOB in Pichia pastoris KM71 cell mitochondria
advantage of the expression in Pichia pastoris compared with the expression in Saccharomyces cerevisiae: a higher level of homogeneity of the isolated enzyme
development of expression systems for human MAO-B and MAO-A, e.g. overexpression in the outer mitochondrial membranes of a Pichia pastoris or a Saccharomyces cerevisiae yeast system
-
expressed in Pichia pastoris
-
expression in a human embryonic kidney cell line and expression in mammalian cells
-
expression in Pichia pastoris
expression in Saccharomyces cerevisiae
expression in Sf21 insect cells
-
expression of hMAO-A and hMAO-B in insect cells BTI-TN-5B1-4 using the baculovirus infection system
-
expression of MAO-A and MAO-B in baculovirus infected BTI insect cells
-
expression of MAO-A in Pichia pastoris mitochondria
expression of wild-type and mutant MAOA in Pichia pastoris KM71 cell mitochondria
expression of wild-type MAO A and mutant MAO A C374A in Pichia pastoris
high level expression in Pichia pastoris
-
high-level expression in Pichia pastoris, higher expression level than in Saccharomyces cerevisiae and higher level of homogeneity of the isolated enzyme
MAO A is encoded on the X chromosome
MAO A, expression in Pichia pastoris strain KM17H
MAO-A and MAO-B are products of two different genes
-
MAOA gene, genotyping in relation to autism spectrum disorder, overview
-
monoamine oxidase A is cloned into the high copy yeast expression vector pEG-KT, to generate a GST MAO-A fusion protein
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
a knockdown of SRY expression substantially reduces both MAO A 2- and 0.24-kb core-promoter activities to below 40% in the transfected cells, overview. R1, i.e. RAM2/CDCA7L/JPO2, a transcription repressor, downregulates MAO A gene expression by competing with Sp1 for binding to Sp1 sites
microRNA-142 reduces monoamine oxidase A expression and activity in neuronal cells by downregulating SIRT1
-
stable overexpression of SRY in the BE(2)C cell line results in ibncreased MAO-A mRNA and catalytic activity levels, SRY increases MAO A-promoter activity up to 6fold in a concentration-dependent manner, overview. Sp1 synergistically enhances the SRY binding to and activation of the MAO A promoter by interacting and forming a transcriptional regulatory complex with SRY at the MAO A core promoter in vivo, Sp4 activates the MAO A core promoter as Sp1. Sp3 represses this activation by competing with Sp1 and Sp4
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
medicine
analysis
drug development
active monoamine oxidase inhibitors represent suitable leads for the development of drugs for neurodegenerative and neuropsychiatric disorders such as Parkinson's disease and depression. Monoamine oxidase inhibitors are also of interest for the treatment of prostate cancer, certain types of cardiomyopathies and Alzheimer's disease
medicine
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Powell, J.F.
Molecular biological studies of monoamine oxidase: structure and function
Biochem. Soc. Trans.
19
199-201
1991
Homo sapiens
Manually annotated by BRENDA team
Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.
High-level expression of human liver monoamine oxidase B in Pichia pastoris
Protein Expr. Purif.
20
334-345
2000
Bos taurus, Homo sapiens
Manually annotated by BRENDA team
Li, M.; Hubalek, F.; Newton-Vinson, P.; Edmondson, D.E.
High-level expression of human liver monoamine oxidase A in Pichia pastoris: comparison with the enzyme expressed in Saccharomyces cerevisiae
Protein Expr. Purif.
24
152-162
2002
Homo sapiens, Homo sapiens (P21397)
Manually annotated by BRENDA team
Nandigama, R.K.; Miller, J.R.; Edmondson, D.E.
Loss of serotonin oxidation as a component of the altered substrate specificity in the Y444F mutant of recombinant human liver MAO A
Biochemistry
40
14839-14846
2001
Homo sapiens
Manually annotated by BRENDA team
Ramsay, R.R.; Singer, T.P.
The kinetic mechanisms of monoamine oxidases A and B
Biochem. Soc. Trans.
19
219-223
1991
Bos taurus, Homo sapiens
Manually annotated by BRENDA team
Tipton, M.F.; Houslay, M.D.; Garrett, N.J.
Rapid screening assay for revertants derived from MSV-transformed cells
Nature
246
213-214
1973
Homo sapiens
Manually annotated by BRENDA team
Norstrand, I.F.; Glantz, M.D.
Purification and properties of human liver monoamine oxidase
Arch. Biochem. Biophys.
158
1-11
1973
Homo sapiens
Manually annotated by BRENDA team
Dennick, R.G.; Mayer, R.J.
Purification and immunochemical characterization of monoamine oxidase from rat and human liver
Biochem. J.
161
167-174
1977
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Pearce, L.B.; Roth, J.A.
Human brain monoamine oxidase: solubilization and kinetics of inhibition by octylglucoside
Arch. Biochem. Biophys.
224
464-472
1983
Homo sapiens
Manually annotated by BRENDA team
Weyler, W.; Salach, J.I.
Purification and properties of mitochondrial monoamine oxidase type A from human placenta
J. Biol. Chem.
260
13199-13207
1985
Homo sapiens
Manually annotated by BRENDA team
Balsa, M.D.; Gomez, N.; Unzeta, M.
Characterization of monoamine oxidase activity present in human granulocytes and lymphocytes
Biochim. Biophys. Acta
992
140-144
1989
Homo sapiens
Manually annotated by BRENDA team
Ramsay, R.R.
Kinetic mechanism of monoamine oxidase A
Biochemistry
30
4624-4629
1991
Homo sapiens
Manually annotated by BRENDA team
Roth, J.A.; Eddy, B.J.
Kinetic properties of membrane-bound and Triton X-100-solubilized human brain monoamine oxidase
Arch. Biochem. Biophys.
205
260-266
1980
Homo sapiens
Manually annotated by BRENDA team
Gottowik, J.; Cesura, A.M.; Malherbe, P.; Lang, G.; Da Prada, M.
Characterization of wild-type and mutant forms of human monoamine oxidase A and B expressed in a mammalian cell line
FEBS Lett.
317
152-156
1993
Homo sapiens
Manually annotated by BRENDA team
Zhou, B.P.; Lewis, D.A.; Kwan, S.W.; Kirksey, T.J.; Abell, C.W.
Mutagenesis at a highly conserved tyrosine in monoamine oxidase B affects FAD incorporation and catalytic activity
Biochemistry
34
9526-9531
1995
Homo sapiens
Manually annotated by BRENDA team
Sablin, S.O.; Ramsay, R.R.
Monoamine oxidase contains a redox-active disulfide
J. Biol. Chem.
273
14074-14076
1998
Homo sapiens
Manually annotated by BRENDA team
Herraiz, T.; Chaparro, C.
Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors
Biochem. Biophys. Res. Commun.
326
378-386
2005
Homo sapiens
Manually annotated by BRENDA team
Ramsay, R.R.; Hunter, D.J.
Inhibitors alter the spectrum and redox properties of monoamine oxidase A
Biochim. Biophys. Acta
1601
178-184
2002
Homo sapiens
Manually annotated by BRENDA team
Edmondson, D.E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F.
Structure and mechanism of monoamine oxidase
Curr. Med. Chem.
11
1983-1993
2004
Homo sapiens
Manually annotated by BRENDA team
Ucar, G.
Substrate specificities of monoamine oxidase isoforms
FABAD J. Pharm. Sci.
27
149-156
2002
Homo sapiens, Rattus norvegicus
-
Manually annotated by BRENDA team
Binda, C.; Hubalek, F.; Li, M.; Edmondson, D.E.; Mattevi, A.
Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane
FEBS Lett.
564
225-228
2004
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Ramonet, D.; Rodriguez, M.; Saura, J.; Lizcano, J.M.; Romera, M.; Unzeta, M.; Finch, C.; Billett, E.; Mahy, N.
Localization of monoamine oxidase A and B and semicarbazide-sensitive amine oxidase in human peripheral tissues
Inflammopharmacology
11
111-117
2003
Homo sapiens
Manually annotated by BRENDA team
Geha, R.M.; Chen, K.; Wouters, J.; Ooms, F.; Shih, J.C.
Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling
J. Biol. Chem.
277
17209-17216
2002
Homo sapiens
Manually annotated by BRENDA team
Markoglou, N.; Hsuesh, R.; Wainer, I.W.
Immobilized enzyme reactors based upon the flavoenzymes monoamine oxidase A and B
J. Chromatogr. B
804
295-302
2004
Homo sapiens
Manually annotated by BRENDA team
Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D.E.; Mattevi, A.
Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class
J. Med. Chem.
47
1767-1774
2004
Homo sapiens (P27338)
Manually annotated by BRENDA team
Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.; Mattevi, A.
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders
Nat. Struct. Biol.
9
22-26
2002
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Dittmann, K.; Riese, U.; Hamburger, M.
HPLC-based bioactivity profiling of plant extracts: a kinetic assay for the identification of monoamine oxidase-A inhibitors using human recombinant monoamine oxidase-A
Phytochemistry
65
2885-2891
2004
Homo sapiens
Manually annotated by BRENDA team
Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D.E.; Mattevi, A.
Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures
Proc. Natl. Acad. Sci. USA
100
9750-9755
2003
Homo sapiens
Manually annotated by BRENDA team
Ucar, G.; Tas, C.; Tuemer, A.
Monoamine oxidase inhibitory activities of the scorpion Mesobuthus gibbosus (Buthidae) venom peptides
Toxicon
45
43-52
2005
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Jones, T.Z.; Fleming, P.; Eyermann, C.J.; Gravestock, M.B.; Ramsay, R.R.
Orientation of oxazolidinones in the active site of monoamine oxidase
Biochem. Pharmacol.
70
407-416
2005
Homo sapiens (P21397)
Manually annotated by BRENDA team
Li, M.; Binda, C.; Mattevi, A.; Edmondson, D.E.
Functional role of the "aromatic cage" in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins
Biochemistry
45
4775-4784
2006
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Vintem, A.P.; Price, N.T.; Silverman, R.B.; Ramsay, R.R.
Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines
Bioorg. Med. Chem.
13
3487-3495
2005
Homo sapiens (P21397)
Manually annotated by BRENDA team
Tao, G.; Irie, Y.; Li, D.J.; Keung, W.M.
Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity
Bioorg. Med. Chem.
13
4777-4788
2005
Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team
Rimoldi, J.M.; Puppali, S.G.; Isin, E.; Bissel, P.; Khalil, A.; Castagnoli, N.
A novel and selective monoamine oxidase B substrate
Bioorg. Med. Chem.
13
5808-5813
2005
Papio hamadryas, Homo sapiens (P21397)
Manually annotated by BRENDA team
Novaroli, L.; Reist, M.; Favre, E.; Carotti, A.; Catto, M.; Carrupt, P.A.
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening
Bioorg. Med. Chem.
13
6212-6217
2005
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Toprakci, M.; Yelekci, K.
Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds
Bioorg. Med. Chem. Lett.
15
4438-4446
2005
Homo sapiens (P27338)
Manually annotated by BRENDA team
Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.
Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N,N-bis[2-oxo-2H-benzopyran]-3-carboxamides
Bioorg. Med. Chem. Lett.
16
4135-4140
2006
Homo sapiens (P21397), Homo sapiens (P27338), Bos taurus (P21398), Bos taurus (P56560)
Manually annotated by BRENDA team
Hubalek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D.E.
Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors
J. Biol. Chem.
280
15761-15766
2005
Equus caballus, Ovis aries, Rattus norvegicus (P19643), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens, Bos taurus (P56560), Bos taurus, Mus musculus (Q8BW75), Mus musculus
Manually annotated by BRENDA team
Ou, X.M.; Chen, K.; Shih, J.C.
Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1
J. Biol. Chem.
281
21512-21525
2006
Homo sapiens
Manually annotated by BRENDA team
Herraiz, T.; Chaparro, C.
Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee
Life Sci.
78
795-802
2006
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Lewitzka, U.; Mueller-Oerlinghausen, B.; Felber, W.; Brunner, J.; Hawellek, B.; Rujescu, D.; Ising, M.; Lauterbach, E.; Broocks, A.; Bondy, B.; Rao, M.L.; Frahnert, C.; Heuser, I.; Hohagen, F.; Maier, W.; Bronisch, T.
Is MAO-B activity in platelets associated with the occurrence of suicidality and behavioural personality traits in depressed patients?
Acta Psychiatr. Scand.
117
41-49
2008
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Nilsson, K.W.; Sjoeberg, R.L.; Wargelius, H.L.; Leppert, J.; Lindstroem, L.; Oreland, L.
The monoamine oxidase A (MAO-A) gene, family function and maltreatment as predictors of destructive behaviour during male adolescent alcohol consumption
Addiction
102
389-398
2007
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Bortolato, M.; Chen, K.; Shih, J.C.
Monoamine oxidase inactivation: From pathophysiology to therapeutics
Adv. Drug Deliv. Rev.
60
1527-1533
2008
Homo sapiens (P21397), Homo sapiens (P27338), Mus musculus (Q64133)
Manually annotated by BRENDA team
Berggren, U.; Eriksson, M.; Fahlke, C.; Blennow, K.; Balldin, J.
Different effects of smoking or use of smokeless tobacco on platelet MAO-B activity in type 1 alcohol-dependent subjects
Alcohol Alcohol.
42
267-271
2007
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Pombo, S.; Levy, P.; Bicho, M.; Ismail, F.; Cardoso, J.M.
Neuropsychological function and platelet monoamine oxidase activity levels in type I alcoholic patients
Alcohol Alcohol.
43
423-430
2008
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Rodriguez-Revenga, L.; Madrigal, I.; Alkhalidi, L.S.; Armengol, L.; Gonzalez, E.; Badenas, C.; Estivill, X.; Mila, M.
Contiguous deletion of the NDP, MAOA, MAOB, and EFHC2 genes in a patient with Norrie disease, severe psychomotor retardation and myoclonic epilepsy
Am. J. Med. Genet. A
143A
916-920
2007
Homo sapiens, Homo sapiens (P21397)
Manually annotated by BRENDA team
Li, J.; Kang, C.; Zhang, H.; Wang, Y.; Zhou, R.; Wang, B.; Guan, L.; Yang, L.; Faraone, S.V.
Monoamine oxidase A gene polymorphism predicts adolescent outcome of attention-deficit/hyperactivity disorder
Am. J. Med. Genet. B Neuropsychiatr. Genet.
144B
430-433
2007
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Li, J.; Wang, Y.; Hu, S.; Zhou, R.; Yu, X.; Wang, B.; Guan, L.; Yang, L.; Zhang, F.; Faraone, S.V.
The monoamine oxidase B gene exhibits significant association to ADHD
Am. J. Med. Genet. B Neuropsychiatr. Genet.
147
370-374
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Li, D.; He, L.
Meta-study on association between the monoamine oxidase A gene (MAOA) and schizophrenia
Am. J. Med. Genet. B Neuropsychiatr. Genet.
147B
174-178
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Prichard, Z.; Mackinnon, A.; Jorm, A.F.; Easteal, S.
No evidence for interaction between MAOA and childhood adversity for antisocial behavior
Am. J. Med. Genet. B Neuropsychiatr. Genet.
147B
228-232
2008
Homo sapiens (P21397)
Manually annotated by BRENDA team
Philibert, R.A.; Gunter, T.D.; Beach, S.R.; Brody, G.H.; Madan, A.
MAOA methylation is associated with nicotine and alcohol dependence in women
Am. J. Med. Genet. B Neuropsychiatr. Genet.
147B
565-570
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Gao, X.; Scott, W.K.; Wang, G.; Mayhew, G.; Li, Y.J.; Vance, J.M.; Martin, E.R.
Gene-gene interaction between FGF20 and MAOB in Parkinson disease
Ann. Hum. Genet.
72
157-162
2008
Homo sapiens (P27338)
Manually annotated by BRENDA team
Palaska, E.; Aydin, F.; Ucar, G.; Erol, D.
Synthesis and monoamine oxidase inhibitory activities of 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-1H-pyrazole derivatives
Arch. Pharm.
341
209-215
2008
Rattus norvegicus (P21396), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Lin, Y.M.; Davamani, F.; Yang, W.C.; Lai, T.J.; Sun, H.S.
Association analysis of monoamine oxidase A gene and bipolar affective disorder in Han Chinese
Behav. Brain Funct.
4
21
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Harkcom, W.T.; Bevan, D.R.
Molecular docking of inhibitors into monoamine oxidase B
Biochem. Biophys. Res. Commun.
360
401-406
2007
Homo sapiens (P27338)
Manually annotated by BRENDA team
Upadhyay, A.K.; Wang, J.; Edmondson, D.E.
Comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membrane-bound forms
Biochemistry
47
526-536
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Bour, S.; Daviaud, D.; Gres, S.; Lefort, C.; Prevot, D.; Zorzano, A.; Wabitsch, M.; Saulnier-Blache, J.S.; Valet, P.; Carpene, C.
Adipogenesis-related increase of semicarbazide-sensitive amine oxidase and monoamine oxidase in human adipocytes
Biochimie
89
916-925
2007
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Brummett, B.H.; Boyle, S.H.; Siegler, I.C.; Kuhn, C.M.; Surwit, R.S.; Garrett, M.E.; Collins, A.; Ashley-Koch, A.; Williams, R.B.
HPA axis function in male caregivers: Effect of the monoamine oxidase-A gene promoter (MAOA-uVNTR)
Biol. Psychol.
79
250-255
2008
Homo sapiens (P21397)
Manually annotated by BRENDA team
Bissel, P.; Khalil, A.; Rimoldi, J.M.; Igarashi, K.; Edmondson, D.; Miller, A.; Castagnoli, N.
Stereochemical studies on the novel monoamine oxidase B substrates (1R,6S)- and (1S,6R)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane
Bioorg. Med. Chem.
16
3557-3564
2008
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Xu, X.; Brookes, K.; Chen, C.; Huang, Y.; Wu, Y.; Asherson, P.
Association study between the monoamine oxidase A gene and attention deficit hyperactivity disorder in Taiwanese samples
BMC Psychiatry
7
10
2007
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Malmberg, K.; Wargelius, H.L.; Lichtenstein, P.; Oreland, L.; Larsson, J.O.
ADHD and disruptive behavior scores - associations with MAO-A and 5-HTT genes and with platelet MAO-B activity in adolescents
BMC Psychiatry
8
28
2008
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Wu, Y.H.; Fischer, D.F.; Swaab, D.F.
A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimers disease patients
Brain Res.
1167
13-19
2007
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Cerasa, A.; Gioia, M.C.; Fera, F.; Passamonti, L.; Liguori, M.; Lanza, P.; Muglia, M.; Magariello, A.; Quattrone, A.
Ventro-lateral prefrontal activity during working memory is modulated by MAO A genetic variation
Brain Res.
1201
114-121
2008
Homo sapiens (P21397)
Manually annotated by BRENDA team
Chen, J.J.; Swope, D.M.; Dashtipour, K.
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinsons disease
Clin. Ther.
29
1825-1849
2007
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Dunkel, P.; Gelain, A.; Barlocco, D.; Haider, N.; Gyires, K.; Sperlagh, B.; Magyar, K.; Maccioni, E.; Fadda, A.; Matyus, P.
Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target
Curr. Med. Chem.
15
1827-1839
2008
Rattus norvegicus, Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team
Zhao, H.; Nolley, R.; Chen, Z.; Reese, S.W.; Peehl, D.M.
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells
Differentiation
76
820-830
2008
Homo sapiens (P21397)
Manually annotated by BRENDA team
Nilsson, K.W.; Wargelius, H.L.; Sjoeberg, R.L.; Leppert, J.; Oreland, L.
The MAO-A gene, platelet MAO-B activity and psychosocial environment in adolescent female alcohol-related problem behaviour
Drug Alcohol Depend.
93
51-62
2008
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Huang, S.Y.; Lin, M.T.; Shy, M.J.; Lin, W.W.; Lin, F.Y.; Lu, R.B.
Neither single-marker nor haplotype analyses support an association between monoamine oxidase A gene and bipolar disorder
Eur. Arch. Psychiatry Clin. Neurosci.
258
350-356
2008
Homo sapiens (P21397)
Manually annotated by BRENDA team
De Luca, V.; Tharmaligam, S.; Strauss, J.; Kennedy, J.L.
5-ht2c receptor and mao-a interaction analysis: no association with suicidal behaviour in bipolar patients
Eur. Arch. Psychiatry Clin. Neurosci.
258
428-433
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Reif, A.; Scarpini, E.; Venturelli, E.; Toepner, T.; Fenoglio, C.; Lesch, K.P.; Galimberti, D.
The functional MAOA-uVNTR promoter polymorphism in patients with frontotemporal dementia
Eur. J. Neurol.
15
637-639
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Izumi, T.; Iwamoto, N.; Kitaichi, Y.; Kato, A.; Inoue, T.; Koyama, T.
Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats
Eur. J. Pharmacol.
565
105-112
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Ballesteros, J.; Maeztu, A.I.; Callado, L.F.; Meana, J.J.; Gutierrez, M.
Specific binding of [3H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death
Eur. Neuropsychopharmacol.
18
55-61
2008
Homo sapiens (P27338)
Manually annotated by BRENDA team
Arrojo, M.; Baca-Garcia, E.; Perez-Rodriguez, M.M.; Dolengevich-Segal, H.; Navio-Acosta, M.; Rodriguez-Salgado, B.; Saiz-Ruiz, J.
Platelet monoamine oxidase activity in obsessive-compulsive disorder
Eur. Psychiatry
22
525-529
2007
Homo sapiens
Manually annotated by BRENDA team
Akkermann, K.; Paaver, M.; Nordquist, N.; Oreland, L.; Harro, J.
Association of 5-HTT gene polymorphism, platelet MAO activity, and drive for thinness in a population-based sample of adolescent girls
Int. J. Eat. Disord.
41
399-404
2008
Homo sapiens
Manually annotated by BRENDA team
Herraiz, T.
Identification and occurrence of beta-carboline alkaloids in raisins and inhibition of monoamine oxidase (MAO)
J. Agric. Food Chem.
55
8534-8540
2007
Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team
Kay, C.W.; El Mkami, H.; Molla, G.; Pollegioni, L.; Ramsay, R.R.
Characterization of the covalently bound anionic flavin radical in monoamine oxidase A by electron paramagnetic resonance
J. Am. Chem. Soc.
129
16091-16097
2007
Homo sapiens (P21397)
Manually annotated by BRENDA team
Leonetti, F.; Capaldi, C.; Pisani, L.; Nicolotti, O.; Muncipinto, G.; Stefanachi, A.; Cellamare, S.; Caccia, C.; Carotti, A.
Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase
J. Med. Chem.
50
4909-4916
2007
Homo sapiens (P27338)
Manually annotated by BRENDA team
Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A.
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs
J. Med. Chem.
50
5848-5852
2007
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Cardia, M.C.; Distinto, S.
Selective inhibitory activity against MAO and molecular modeling studies of 2-thiazolylhydrazone derivatives
J. Med. Chem.
50
707-712
2007
Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team
Akyuez, M.A.; Erdem, S.S.; Edmondson, D.E.
The aromatic cage in the active site of monoamine oxidase B: effect on the structural and electronic properties of bound benzylamine and p-nitrobenzylamine
J. Neural Transm.
114
693-698
2007
Homo sapiens (P27338)
Manually annotated by BRENDA team
Cruz, F.; Edmondson, D.E.
Kinetic properties of recombinant MAO-A on incorporation into phospholipid nanodisks
J. Neural Transm.
114
699-702
2007
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Nordquist, N.; Oreland, L.
Monoallelic expression of MAO-A in skin fibroblasts
J. Neural Transm.
114
713-716
2007
Homo sapiens (P21397)
Manually annotated by BRENDA team
Wang, J.; Edmondson, D.E.
Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-As
J. Neural Transm.
114
721-724
2007
Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Alia-Klein, N.; Goldstein, R.Z.; Kriplani, A.; Logan, J.; Tomasi, D.; Williams, B.; Telang, F.; Shumay, E.; Biegon, A.; Craig, I.W.; Henn, F.; Wang, G.J.; Volkow, N.D.; Fowler, J.S.
Brain monoamine oxidase A activity predicts trait aggression
J. Neurosci.
28
5099-5104
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
ORourke, A.M.; Wang, E.Y.; Miller, A.; Podar, E.M.; Scheyhing, K.; Huang, L.; Kessler, C.; Gao, H.; Ton-Nu, H.T.; Macdonald, M.T.; Jones, D.S.; Linnik, M.D.
Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity
J. Pharmacol. Exp. Ther.
324
867-875
2008
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Baler, R.D.; Volkow, N.D.; Fowler, J.S.; Benveniste, H.
Is fetal brain monoamine oxidase inhibition the missing link between maternal smoking and conduct disorders?
J. Psychiatry Neurosci.
33
187-195
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Gabilondo, A.M.; Hostalot, C.; Garibi, J.M.; Meana, J.J.; Callado, L.F.
Monoamine oxidase B activity is increased in human gliomas
Neurochem. Int.
52
230-234
2008
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Cicin-Sain, L.; Matosic, A.; Mokrovic, G.; Balija, M.; Marusic, S.; Jernej, B.
Platelet monoamine oxidase kinetics, alcoholism subtypes and cigarette smoking
Neuropsychobiology
56
138-145
2007
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Kersting, A.; Kroker, K.; Horstmann, J.; Baune, B.T.; Hohoff, C.; Mortensen, L.S.; Neumann, L.C.; Arolt, V.; Domschke, K.
Association of MAO-A variant with complicated grief in major depression
Neuropsychobiology
56
191-196
2007
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Sjoeberg, R.L.; Ducci, F.; Barr, C.S.; Newman, T.K.; Dellosso, L.; Virkkunen, M.; Goldman, D.
A non-additive interaction of a functional MAO-A VNTR and testosterone predicts antisocial behavior
Neuropsychopharmacology
33
425-430
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Frazzetto, G.; Di Lorenzo, G.; Carola, V.; Proietti, L.; Sokolowska, E.; Siracusano, A.; Gross, C.; Troisi, A.
Early trauma and increased risk for physical aggression during adulthood: the moderating role of MAOA genotype
PLoS ONE
2
e486
2007
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Mallajosyula, J.K.; Kaur, D.; Chinta, S.J.; Rajagopalan, S.; Rane, A.; Nicholls, D.G.; Di Monte, D.A.; Macarthur, H.; Andersen, J.K.
MAO-B elevation in mouse brain astrocytes results in Parkinsons pathology
PLoS ONE
3
e1616
2008
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Culpepper, L.; Kovalick, L.J.
A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression
Prim. Care Companion J. Clin. Psychiatry
10
25-30
2008
Homo sapiens
Manually annotated by BRENDA team
Tadic, A.; Rujescu, D.; Mueller, M.J.; Kohnen, R.; Stassen, H.H.; Dahmen, N.; Szegedi, A.
A monoamine oxidase B gene variant and short-term antidepressant treatment response
Prog. Neuropsychopharmacol. Biol. Psychiatry
31
1370-1377
2007
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Muck-Seler, D.; Sagud, M.; Mustapic, M.; Nedic, G.; Babic, A.; Mihaljevic Peles, A.; Jakovljevic, M.; Pivac, N.
The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression
Prog. Neuropsychopharmacol. Biol. Psychiatry
32
1195-1198
2008
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Domschke, K.; Hohoff, C.; Mortensen, L.S.; Roehrs, T.; Deckert, J.; Arolt, V.; Baune, B.T.
Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression
Prog. Neuropsychopharmacol. Biol. Psychiatry
32
224-228
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Lee, B.C.; Yang, J.W.; Lee, S.H.; Kim, S.H.; Joe, S.H.; Jung, I.K.; Choi, I.G.; Ham, B.J.
An interaction between the norepinephrine transporter and monoamine oxidase A polymorphisms, and novelty-seeking personality traits in Korean females
Prog. Neuropsychopharmacol. Biol. Psychiatry
32
238-242
2008
Homo sapiens (P21397)
Manually annotated by BRENDA team
Alia-Klein, N.; Kriplani, A.; Pradhan, K.; Ma, J.Y.; Logan, J.; Williams, B.; Craig, I.W.; Telang, F.; Tomasi, D.; Goldstein, R.Z.; Wang, G.J.; Volkow, N.D.; Fowler, J.S.
The MAO-A genotype does not modulate resting brain metabolism in adults
Psychiatry Res.
164
73-76
2008
Homo sapiens (P21397)
Manually annotated by BRENDA team
Guersoy, S.; Erdal, E.; Sezgin, M.; Barlas, I.O.; Aydeniz, A.; Alasehirli, B.; Sahin, G.
Which genotype of MAO gene that the patients have are likely to be most susceptible to the symptoms of fibromyalgia?
Rheumatol. Int.
28
307-311
2008
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Lecht, S.; Haroutiunian, S.; Hoffman, A.; Lazarovici, P.
Rasagiline - a novel MAO B inhibitor in Parkinsons disease therapy
Ther. Clin. Risk Manag.
3
467-474
2007
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Buckholtz, J.W.; Meyer-Lindenberg, A.
MAOA and the neurogenetic architecture of human aggression
Trends Neurosci.
31
120-129
2008
Homo sapiens (P21397)
Manually annotated by BRENDA team
Upadhyay, A.K.; Borbat, P.P.; Wang, J.; Freed, J.H.; Edmondson, D.E.
Determination of the oligomeric states of human and rat monoamine oxidases in the outer mitochondrial membrane and octyl beta-D-glucopyranoside micelles using pulsed dipolar electron spin resonance spectroscopy
Biochemistry
47
1554-1566
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Binda, C.; Wang, J.; Li, M.; Hubalek, F.; Mattevi, A.; Edmondson, D.E.
Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B
Biochemistry
47
5616-5625
2008
Homo sapiens, Homo sapiens (P27338)
Manually annotated by BRENDA team
Upadhyay, A.K.; Edmondson, D.E.
Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B
Biochemistry
48
3928-3935
2009
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Gooden, D.M.; Schmidt, D.M.; Pollock, J.A.; Kabadi, A.M.; McCafferty, D.G.
Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B
Bioorg. Med. Chem. Lett.
18
3047-3051
2008
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Van der Walt, E.M.; Milczek, E.M.; Malan, S.F.; Edmondson, D.E.; Castagnoli, N.; Bergh, J.J.; Petzer, J.P.
Inhibition of monoamine oxidase by (E)-styrylisatin analogues
Bioorg. Med. Chem. Lett.
19
2509-2513
2009
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Zhao, H.; Flamand, V.; Peehl, D.M.
Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells
BMC Med. Genomics
2
55
2009
Homo sapiens
Manually annotated by BRENDA team
Wu, J.B.; Chen, K.; Li, Y.; Lau, Y.F.; Shih, J.C.
Regulation of monoamine oxidase A by the SRY gene on the Y chromosome
FASEB J.
23
4029-4038
2009
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Dunn, R.V.; Marshall, K.R.; Munro, A.W.; Scrutton, N.S.
The pH dependence of kinetic isotope effects in monoamine oxidase A indicates stabilization of the neutral amine in the enzyme-substrate complex
FEBS J.
275
3850-3858
2008
Homo sapiens (P21397)
Manually annotated by BRENDA team
Wang, J.; Harris, J.; Mousseau, D.D.; Edmondson, D.E.
Mutagenic probes of the role of Ser209 on the cavity shaping loop of human monoamine oxidase A
FEBS J.
276
4569-4581
2009
Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
van Diermen, D.; Marston, A.; Bravo, J.; Reist, M.; Carrupt, P.A.; Hostettmann, K.
Monoamine oxidase inhibition by Rhodiola rosea L. roots
J. Ethnopharmacol.
122
397-401
2009
Homo sapiens (P27338)
Manually annotated by BRENDA team
Milczek, E.M.; Bonivento, D.; Binda, C.; Mattevi, A.; McDonald, I.A.; Edmondson, D.E.
Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B
J. Med. Chem.
51
8019-8026
2008
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Yoo, H.J.; Lee, S.K.; Park, M.; Cho, I.H.; Hyun, S.H.; Lee, J.C.; Yang, S.Y.; Kim, S.A.
Family- and population-based association studies of monoamine oxidase A and autism spectrum disorders in Korean
Neurosci. Res.
63
172-176
2009
Homo sapiens
Manually annotated by BRENDA team
Petzer, J.P.; Castagnoli, N.; Schwarzschild, M.A.; Chen, J.F.; Van der Schyf, C.J.
Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinsons disease
Neurotherapeutics
6
141-151
2009
Mus musculus, Homo sapiens (P27338)
Manually annotated by BRENDA team
van der Vegt, E.J.; Oostra, B.A.; Arias-Vasquez, A.; van der Ende, J.; Verhulst, F.C.; Tiemeier, H.
High activity of monoamine oxidase A is associated with externalizing behaviour in maltreated and nonmaltreated adoptees
Psychiatr. Genet.
19
209-211
2009
Homo sapiens
Manually annotated by BRENDA team
Saidemberg, D.M.; Ferreira, M.A.; Takahashi, T.N.; Gomes, P.C.; Cesar-Tognoli, L.M.; da Silva-Filho, L.C.; Tormena, C.F.; da Silva, G.V.; Palma, M.S.
Monoamine oxidase inhibitory activities of indolylalkaloid toxins from the venom of the colonial spider Parawixia bistriata: functional characterization of PwTX-I
Toxicon
54
717-724
2009
Homo sapiens
Manually annotated by BRENDA team
Ravikumar, K.; Sridhar, B.
Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B
Acta Crystallogr. Sect. C
66
o317-o320
2010
Homo sapiens
Manually annotated by BRENDA team
Shen, H.W.; Wu, C.; Jiang, X.L.; Yu, A.M.
Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics
Biochem. Pharmacol.
80
122-128
2010
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, A.
Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases
Biochemistry
48
4220-4230
2009
Bos taurus, Homo sapiens, Mus musculus, Rattus norvegicus
Manually annotated by BRENDA team
Jia, Z.; Wei, S.; Zhu, Q.
Monoamine oxidase inhibitors: benzylidene-prop-2-ynyl-amines analogues
Biol. Pharm. Bull.
33
725-728
2010
Homo sapiens
Manually annotated by BRENDA team
Alcaro, S.; Gaspar, A.; Ortuso, F.; Milhazes, N.; Orallo, F.; Uriarte, E.; Yanez, M.; Borges, F.
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B
Bioorg. Med. Chem. Lett.
20
2709-2712
2010
Homo sapiens
Manually annotated by BRENDA team
Geldenhuys, W.J.; Darvesh, A.S.; Funk, M.O.; Van der Schyf, C.J.; Carroll, R.T.
Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening
Bioorg. Med. Chem. Lett.
20
5295-5298
2010
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Strydom, B.; Malan, S.F.; Castagnoli, N.; Bergh, J.J.; Petzer, J.P.
Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues
Bioorg. Med. Chem.
18
1018-1028
2010
Homo sapiens, Papio anubis
Manually annotated by BRENDA team
Luehr, S.; Vilches-Herrera, M.; Fierro, A.; Ramsay, R.R.; Edmondson, D.E.; Reyes-Parada, M.; Cassels, B.K.; Iturriaga-Vasquez, P.
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors
Bioorg. Med. Chem.
18
1388-1395
2010
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Maccioni, E.; Cardia, M.C.; Yanez, M.; Orallo, F.; Alcaro, S.; Ortuso, F.; Cirilli, R.; Ferretti, R.; Distinto, S.; Kirchmair, J.; Langer, T.
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors
Bioorg. Med. Chem.
18
5063-5070
2010
Homo sapiens
Manually annotated by BRENDA team
Chimenti, F.; Bolasco, A.; Secci, D.; Chimenti, P.; Granese, A.; Carradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S.
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors
Bioorg. Med. Chem.
18
5715-5723
2010
Homo sapiens
Manually annotated by BRENDA team
Ke, S.; Qian, X.; Liu, F.; Wang, N.; Yang, Q.; Li, Z.
Novel 4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains: design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis and tumor cell
Eur. J. Med. Chem.
44
2113-2121
2009
Homo sapiens
Manually annotated by BRENDA team
Prins, L.H.; Petzer, J.P.; Malan, S.F.
Inhibition of monoamine oxidase by indole and benzofuran derivatives
Eur. J. Med. Chem.
45
4458-4466
2010
Homo sapiens (P27338)
Manually annotated by BRENDA team
Maccioni, E.; Alcaro, S.; Orallo, F.; Cardia, M.C.; Distinto, S.; Costa, G.; Yanez, M.; Sanna, M.L.; Vigo, S.; Meleddu, R.; Secci, D.
Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase
Eur. J. Med. Chem.
45
4490-4498
2010
Homo sapiens
Manually annotated by BRENDA team
Herraiz, T.; Gonzalez, D.; Ancin-Azpilicueta, C.; Aran, V.J.; Guillen, H.
beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)
Food Chem. Toxicol.
48
839-845
2010
Homo sapiens
Manually annotated by BRENDA team
Herraiz, T.; Aran, V.J.; Guillen, H.
Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO)
Free Radic. Res.
43
975-984
2009
Homo sapiens
Manually annotated by BRENDA team
Hu, K.; Zhang, L.; Li, X.; Zhao, S.
Rapid screening of monoamine oxidase B inhibitors in natural extracts by capillary electrophoresis after enzymatic reaction at capillary inlet
J. Chromatogr. B
878
3156-3160
2010
Homo sapiens
Manually annotated by BRENDA team
Goren, T.; Adar, L.; Sasson, N.; Weiss, Y.M.
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline
J. Clin. Pharmacol.
50
1420-1428
2010
Homo sapiens
Manually annotated by BRENDA team
Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S.
Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins
J. Med. Chem.
52
1935-1942
2009
Homo sapiens
Manually annotated by BRENDA team
Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S.
Chalcones: a valid scaffold for monoamine oxidases inhibitors
J. Med. Chem.
52
2818-2824
2009
Homo sapiens
Manually annotated by BRENDA team
Dreiseitel, A.; Korte, G.; Schreier, P.; Oehme, A.; Locher, S.; Domani, M.; Hajak, G.; Sand, P.G.
Berry anthocyanins and their aglycons inhibit monoamine oxidases A and B
Pharmacol. Res.
59
306-311
2009
Homo sapiens
Manually annotated by BRENDA team
Ramsay, R.R.; Olivieri, A.; Holt, A.
An improved approach to steady-state analysis of monoamine oxidases
J. Neural Transm.
118
1003-1019
2011
Homo sapiens (P27338)
Manually annotated by BRENDA team
McDonald, G.R.; Olivieri, A.; Ramsay, R.R.;, Holt, A.
On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B
Pharmacol. Res.
62
475-488
2010
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Carroll, R.T.; Dluzen, D.E.; Stinnett, H.; Awale, P.S.; Funk, M.O.; Geldenhuys, W.J.
Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B
Bioorg. Med. Chem. Lett.
21
4798-4803
2011
Homo sapiens
Manually annotated by BRENDA team
Milczek, E.M.; Binda, C.; Rovida, S.; Mattevi, A.; Edmondson, D.E.
The gating residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition
FEBS J.
278
4860-4869
2011
Homo sapiens
Manually annotated by BRENDA team
Mathew, B.; Mathew, G.E.; Ucar, G.; Baysal, I.; Suresh, J.; Vilapurathu, J.K.; Prakasan, A.; Suresh, J.K.; Thomas, A.
Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors Synthesis, biochemistry and molecular docking studies
Bioorg. Chem.
62
22-29
2015
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Sun, Y.; Chen, J.; Chen, X.; Huang, L.; Li, X.
Inhibition of cholinesterase and monoamine oxidase-B activity by tacrine-homoisoflavonoid hybrids
Bioorg. Med. Chem.
21
7406-7417
2013
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Tzvetkov, N.T.; Stammler, H.G.; Neumann, B.; Hristova, S.; Antonov, L.; Gastreich, M.
Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors
Eur. J. Med. Chem.
127
470-492
2017
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team
Bonaiuto, E.; Milelli, A.; Cozza, G.; Tumiatti, V.; Marchetti, C.; Agostinelli, E.; Fimognari, C.; Hrelia, P.; Minarini, A.; Di Paolo, M.L.
Novel polyamine analogues from substrates towards potential inhibitors of monoamine oxidases
Eur. J. Med. Chem.
70
88-101
2013
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Dasgupta, S.; Mukherjee, S.; Mukhopadhyay, B.P.; Banerjee, A.; Mishra, D.K.
Recognition dynamics of dopamine to human monoamine oxidase B role of Leu171/Gln206 and conserved water molecules in the active site cavity
J. Biomol. Struct. Dyn.
24
1-24
2017
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Chaudhuri, A.D.; Yelamanchili, S.V.; Fox, H.S.
MicroRNA-142 reduces monoamine oxidase A expression and activity in neuronal cells by downregulating SIRT1
PLoS ONE
8
e79579
2013
Homo sapiens
Manually annotated by BRENDA team
Qazi, S.; Naz, A.; Hameed, A.; Osra, F.; Jalil, S.; Iqbal, J.; Shah, S.; Mirza, A.
Semicarbazones, thiosemicarbazone, thiazole and oxazole analogues as monoamine oxidase inhibitors Synthesis, characterization, biological evaluation, molecular docking, and kinetic studies
Bioorg. Chem.
115
116165
2021
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Ahmad, S.; Zaib, S.; Jalil, S.; Shafiq, M.; Ahmad, M.; Sultan, S.; Iqbal, M.; Aslam, S.; Iqbal, J.
Synthesis, characterization, monoamine oxidase inhibition, molecular docking and dynamic simulations of novel 2,1-benzothiazine-2,2-dioxide derivatives
Bioorg. Chem.
80
498-510
2018
Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team
Qhobosheane, M.; Legoabe, L.; Petzer, A.; Petzer, J.
The monoamine oxidase inhibition properties of C6-mono- and N3/C6-disubstituted derivatives of 4(3H)-quinazolinone
Bioorg. Chem.
85
60-65
2019
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Cheng, K.; Li, S.; Lv, X.; Tian, Y.; Kong, H.; Huang, X.; Duan, Y.; Han, J.; Xie, Z.; Liao, C.
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure
Bioorg. Med. Chem. Lett.
29
1012-1018
2019
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Chirkova, Z.; Kabanova, M.; Filimonov, S.; Abramov, I.; Petzer, A.; Engelbrecht, I.; Petzer, J.; Yu Suponitsky, K.; Veselovsky, A.
An investigation of the monoamine oxidase inhibition properties of pyrrolo[3,4-f]indole-5,7-dione and indole-5,6-dicarbonitrile derivatives
Drug Dev. Res.
79
81-93
2018
Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team
Herraiz, T.; Flores, A.; Fernandez, L.
Analysis of monoamine oxidase (MAO) enzymatic activity by high-performance liquid chromatography-diode array detection combined with an assay of oxidation with a peroxidase and its application to MAO inhibitors from foods and plants
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
1073
136-144
2018
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Reis, J.; Manzella, N.; Cagide, F.; Mialet-Perez, J.; Uriarte, E.; Parini, A.; Borges, F.; Binda, C.
Tight-binding inhibition of human monoamine oxidase B by chromone analogs a kinetic, crystallographic, and biological analysis
J. Med. Chem.
61
4203-4212
2018
Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Yang, D.; Wang, R.; Zhu, J.; Cao, Q.; Qin, J.; Zhu, H.; Qian, S.
Synthesis, crystal structures, molecular docking, vitro monoamine oxidase-B inhibitory activity of transition metal complexes with 2-{4-[bis (4-fluorophenyl)methyl]piperazin-1-yl} acetic acid
J. Mol. Struct.
1128
493-498
2017
Rattus norvegicus (P19643), Homo sapiens (P27338)
-
Manually annotated by BRENDA team
Ramsay, R.; Albreht, A.
Kinetics, mechanism, and inhibition of monoamine oxidase
J. Neural Transm.
125
1659-1683
2018
Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team